Gene Gene synonym Ensembl Gene description Chromosome Position Protein class Evidence Antibody Reliability (IH) Reliability (Mouse Brain) Reliability (IF) Subcellular location Prognostic p-value RNA cancer category RNA tissue category RNA TS RNA TS TPM TPM max in non-specific ABAT GABAT ENSG00000183044 4-aminobutyrate aminotransferase 16 8674565-8784575 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA041528, HPA041690 Supported Supported Mitochondria Renal cancer:5.44e-8 (favourable), Liver cancer:5.36e-5 (favourable), Lung cancer:5.93e-4 (favourable) Expressed in all Tissue enhanced cerebral cortex: 165.0;kidney: 134.3;liver: 175.2 thyroid gland: 47.2 ABCA1 ABC1, HDLDT1, TGD ENSG00000165029 ATP-binding cassette, sub-family A (ABC1), member 1 9 104781002-104928237 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA057283, CAB069889 Approved Approved Nucleoplasm
Vesicles Expressed in all Mixed adrenal gland: 38.1 ABCC1 GS-X, MRP, MRP1 ENSG00000103222 ATP-binding cassette, sub-family C (CFTR/MRP), member 1 16 15949577-16143074 Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA002380 Uncertain Supported Plasma membrane Renal cancer:1.55e-6 (unfavourable), Liver cancer:5.42e-5 (unfavourable) Expressed in all Mixed parathyroid gland: 18.1 ABCC2 CMOAT, cMRP, DJS, MRP2 ENSG00000023839 ATP-binding cassette, sub-family C (CFTR/MRP), member 2 10 99782732-99852192 Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA004860, CAB037271 Approved Renal cancer:1.93e-5 (unfavourable) Tissue enhanced Group enriched 10 duodenum: 44.7;gallbladder: 42.8;kidney: 20.8;liver: 67.6;small intestine: 50.5 breast: 4.3 ABCC8 ABC36, HHF1, HI, HRINS, MRP8, PHHI, SUR, SUR1, TNDM2 ENSG00000006071 ATP-binding cassette, sub-family C (CFTR/MRP), member 8 11 17392885-17476845 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB011451, HPA042318 Approved Approved Nucleoli
Golgi apparatus
Cytosol Tissue enriched Tissue enhanced cerebral cortex: 11.7 adrenal gland: 7.6 ABL1 ABL, c-ABL, JTK7, p150 ENSG00000097007 ABL proto-oncogene 1, non-receptor tyrosine kinase 9 130713946-130887675 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB002686, HPA027251, HPA027280, HPA028409 Supported Validated Nucleoplasm
Nuclear bodies Expressed in all Expressed in all parathyroid gland: 82.2 ACAA1 ENSG00000060971 Acetyl-CoA acyltransferase 1 3 38103129-38137242 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA006764, HPA007244 Supported Validated Peroxisomes Renal cancer:6.99e-9 (favourable), Head and neck cancer:1.23e-4 (favourable), Breast cancer:3.00e-4 (favourable), Endometrial cancer:7.53e-4 (favourable) Expressed in all Expressed in all liver: 327.6 ACE ACE1, CD143, DCP1 ENSG00000159640 Angiotensin I converting enzyme 17 63477061-63498380 Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB002426, CAB002921, HPA029298, HPA069790 Supported Approved Vesicles Expressed in all Tissue enhanced duodenum: 183.8;small intestine: 297.5 testis: 83.7 ACE2 ENSG00000130234 Angiotensin I converting enzyme 2 X 15561033-15602148 Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA000288, CAB026174 Supported Renal cancer:2.12e-5 (favourable), Liver cancer:4.21e-4 (favourable) Tissue enhanced Group enriched 6 duodenum: 186.1;gallbladder: 100.6;kidney: 93.3;small intestine: 266.6;testis: 92.6 heart muscle: 23.1 ACHE YT ENSG00000087085 Acetylcholinesterase (Yt blood group) 7 100889994-100896974 Blood group antigen proteins, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA019704, HPA027098 Approved Golgi apparatus
Vesicles Renal cancer:3.88e-5 (unfavourable), Glioma:7.16e-4 (unfavourable) Mixed Tissue enhanced skeletal muscle: 58.5 cerebral cortex: 14.1 ADA ENSG00000196839 Adenosine deaminase 20 44619522-44652233 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA001399, CAB004307, HPA023884 Supported Renal cancer:2.94e-14 (unfavourable), Endometrial cancer:1.23e-7 (unfavourable), Liver cancer:6.77e-5 (unfavourable), Lung cancer:2.20e-4 (unfavourable) Expressed in all Tissue enriched 14 duodenum: 501.3 lymph node: 37.0 ADH1A ADH1 ENSG00000187758 Alcohol dehydrogenase 1A (class I), alpha polypeptide 4 99276367-99291028 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB009562, HPA047814, HPA060902 Supported Approved Plasma membrane
Cytosol Liver cancer:2.38e-4 (favourable) Tissue enriched Tissue enriched 134 liver: 1364.4 gallbladder: 10.2 ADH1B ADH2 ENSG00000196616 Alcohol dehydrogenase 1B (class I), beta polypeptide 4 99304964-99321401 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA047814, HPA060902 Supported Approved Plasma membrane
Cytosol Renal cancer:7.87e-4 (unfavourable) Tissue enriched Group enriched 6 adipose tissue: 1534.1;liver: 2889.4 lung: 371.7 ADH1C ADH3 ENSG00000248144 Alcohol dehydrogenase 1C (class I), gamma polypeptide 4 99336492-99353027 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA047814, HPA060902 Supported Approved Nucleoplasm
Plasma membrane
Cytosol Lung cancer:2.99e-4 (favourable), Liver cancer:4.55e-4 (favourable) Tissue enriched Tissue enhanced duodenum: 522.4;liver: 886.9;stomach: 478.6 colon: 281.0 ADK AK ENSG00000156110 Adenosine kinase 10 74151185-74709303 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level CAB032876, HPA038391, HPA038409 Approved Supported Nucleoplasm
Cytosol Head and neck cancer:1.93e-4 (unfavourable), Liver cancer:9.91e-4 (favourable) Expressed in all Expressed in all liver: 77.4 ADORA1 RDC7 ENSG00000163485 Adenosine A1 receptor 1 203090654-203167405 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level HPA044383 Supported Plasma membrane Tissue enhanced Tissue enhanced cerebral cortex: 46.5;testis: 23.4 parathyroid gland: 17.5 ADORA2A ADORA2, RDC8 ENSG00000128271 Adenosine A2a receptor 22 24417879-24442360 Cancer-related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level Not detected Tissue enhanced bone marrow: 9.6 lymph node: 7.7 ADORA2B ENSG00000170425 Adenosine A2b receptor 17 15944917-15975746 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA073747 Uncertain Cytosol Mixed Mixed colon: 8.3 ADORA3 AD026 ENSG00000282608 Adenosine A3 receptor 1 111499429-111503760 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level Mixed adrenal gland: 18.5 ADRA1A ADRA1C, ADRA1L1 ENSG00000120907 Adrenoceptor alpha 1A 8 26748150-26867273 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA029678, HPA029679 Approved Tissue enhanced Tissue enhanced adipose tissue: 22.6;liver: 32.0 seminal vesicle: 19.5 ADRA1B ENSG00000170214 Adrenoceptor alpha 1B 5 159916783-159972544 Cancer-related genes, FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA074416 Supported Plasma membrane Renal cancer:1.40e-6 (unfavourable), Thyroid cancer:3.19e-5 (favourable), Endometrial cancer:6.00e-5 (unfavourable), Ovarian cancer:2.67e-4 (favourable), Glioma:6.07e-4 (unfavourable) Mixed Tissue enhanced cerebral cortex: 14.8;spleen: 17.3 ovary: 4.8 ADRA1D ADRA1, ADRA1A, ADRA1R ENSG00000171873 Adrenoceptor alpha 1D 20 4220631-4249074 FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins Evidence at transcript level HPA038789 Uncertain Mixed Tissue enhanced cervix, uterine: 4.3;prostate: 4.2 seminal vesicle: 2.5 ADRA2A ADRA2, ADRA2R, ADRAR ENSG00000150594 Adrenoceptor alpha 2A 10 111077163-111080907 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level Endometrial cancer:8.06e-4 (favourable) Expressed in all Mixed cervix, uterine: 33.1 ADRA2C ADRA2L2, ADRA2RL2, ADRARL2 ENSG00000184160 Adrenoceptor alpha 2C 4 3766348-3768526 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA057688 Uncertain Mixed Tissue enhanced cervix, uterine: 21.0;endometrium: 26.0;seminal vesicle: 26.7 fallopian tube: 7.9 ADRB1 ADRB1R ENSG00000043591 Adrenoceptor beta 1 10 114044056-114046908 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA067972 Supported Tissue enriched Tissue enhanced placenta: 45.2 heart muscle: 11.9 ADRB2 ADRB2R, ADRBR, B2AR, BAR ENSG00000169252 Adrenoceptor beta 2, surface 5 148825245-148828687 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level HPA003431, HPA075322 Uncertain Uncertain Cytosol Renal cancer:3.15e-9 (favourable) Mixed Mixed lung: 16.3 ADRB3 ENSG00000188778 Adrenoceptor beta 3 8 37962991-37966965 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level Not detected Tissue enhanced ovary: 10.0;placenta: 4.1 gallbladder: 2.6 AGTR1 AG2S, AGTR1A, AGTR1B, AT1, AT1B, AT2R1, AT2R1A, AT2R1B, HAT1R ENSG00000144891 Angiotensin II receptor, type 1 3 148697784-148743008 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level HPA003596 Supported Uncertain Vesicles Group enriched Tissue enhanced placenta: 212.0 liver: 50.8 AKR1C2 BABP, DD, DD2, DDH2, HAKRD, MCDR2, TDD ENSG00000151632 Aldo-keto reductase family 1, member C2 10 4922564-5135226 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level CAB047304, HPA068265 Approved Approved Nucleus
Nucleoli fibrillar center
Endoplasmic reticulum
Cytosol Group enriched Group enriched 5 adipose tissue: 352.3;breast: 122.0;esophagus: 118.4;gallbladder: 189.9;liver: 186.5;stomach: 138.5;urinary bladder: 186.3 duodenum: 33.7 AKR1D1 SRD5B1 ENSG00000122787 Aldo-keto reductase family 1, member D1 7 138002324-138117986 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA057002 Supported Approved Nucleoplasm
Cytosol Liver cancer:9.91e-5 (favourable) Tissue enriched Tissue enriched 32 liver: 229.0 breast: 7.1 ALAD ALADH, PBGS ENSG00000148218 Aminolevulinate dehydratase 9 113386317-113401333 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA021023, HPA022124 Supported Colorectal cancer:7.33e-5 (unfavourable), Liver cancer:8.80e-5 (favourable), Renal cancer:1.65e-4 (favourable), Endometrial cancer:5.64e-4 (favourable) Expressed in all Expressed in all adrenal gland: 147.9 ALDH2 ENSG00000111275 Aldehyde dehydrogenase 2 family (mitochondrial) 12 111766887-111817529 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA051065 Approved Liver cancer:3.95e-7 (favourable), Renal cancer:5.24e-6 (favourable), Endometrial cancer:2.63e-4 (favourable), Urothelial cancer:7.71e-4 (unfavourable) Expressed in all Expressed in all liver: 440.7 ALK CD246 ENSG00000171094 Anaplastic lymphoma receptor tyrosine kinase 2 29192774-29921566 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA010694 Approved Supported Plasma membrane Group enriched Tissue enhanced cerebral cortex: 3.5;testis: 2.3 adrenal gland: 0.9 ALOX5 5-LOX ENSG00000012779 Arachidonate 5-lipoxygenase 10 45374176-45446119 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA071285 Supported Supported Nucleoplasm Renal cancer:1.80e-5 (unfavourable), Urothelial cancer:7.18e-4 (favourable) Expressed in all Tissue enhanced lung: 41.4 bone marrow: 28.9 ALPPL2 ENSG00000163286 Alkaline phosphatase, placental-like 2 2 232406843-232410714 Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB020698, HPA038764, HPA038765, HPA051699 Supported Approved Plasma membrane Tissue enhanced Tissue enhanced cervix, uterine: 1.1;fallopian tube: 1.9 lung: 0.7 AMY2A AMY2 ENSG00000243480 Amylase, alpha 2A (pancreatic) 1 103616811-103625780 Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at protein level HPA045394, HPA045399, CAB045960, HPA046980 Supported Tissue enriched Tissue enriched 313 pancreas: 31311.3 ovary: 100.1 ANO1 DOG1, FLJ10261, ORAOV2, TAOS2, TMEM16A ENSG00000131620 Anoctamin 1, calcium activated chloride channel 11 70078302-70189528 FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA032148 Supported Renal cancer:4.09e-6 (unfavourable), Endometrial cancer:4.58e-6 (favourable), Head and neck cancer:7.28e-5 (unfavourable), Pancreatic cancer:1.70e-4 (unfavourable), Lung cancer:2.40e-4 (unfavourable) Expressed in all Tissue enhanced epididymis: 217.7;seminal vesicle: 295.7 skin: 116.0 ANXA1 ANX1, LPC1 ENSG00000135046 Annexin A1 9 73151757-73170393 Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transporters Evidence at protein level HPA011271, HPA011272, CAB013023, CAB035987, CAB058693 Supported Validated Nucleoplasm
Plasma membrane
Cytosol Urothelial cancer:6.19e-6 (unfavourable), Thyroid cancer:4.57e-5 (favourable), Endometrial cancer:5.71e-5 (favourable) Expressed in all Tissue enriched 6 esophagus: 7577.8 tonsil: 1266.5 AOC3 HPAO, VAP-1, VAP1 ENSG00000131471 Amine oxidase, copper containing 3 17 42851184-42858130 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA000980, CAB025797 Supported Approved Golgi apparatus
Cytosol Renal cancer:1.79e-5 (unfavourable), Colorectal cancer:3.68e-4 (unfavourable), Urothelial cancer:6.98e-4 (unfavourable) Expressed in all Tissue enhanced adipose tissue: 449.0 smooth muscle: 203.0 APEX1 APE, APE-1, APEN, APEX, APX, HAP1, REF-1, REF1 ENSG00000100823 APEX nuclease (multifunctional DNA repair enzyme) 1 14 20455191-20457772 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA000956, HPA002564, CAB004294, CAB047307 Supported Validated Nucleus Liver cancer:7.82e-5 (unfavourable) Expressed in all Expressed in all ovary: 176.0 AR AIS, DHTR, HUMARA, NR3C4, SBMA, SMAX1 ENSG00000169083 Androgen receptor X 67544032-67730619 Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB000001, HPA065701, CAB065764 Supported Approved Mitochondria Renal cancer:1.03e-8 (favourable), Liver cancer:8.77e-4 (favourable) Mixed Mixed fallopian tube: 42.6 ASIC1 ACCN2, BNaC2, hBNaC2 ENSG00000110881 Acid sensing (proton gated) ion channel 1 12 50057548-50083611 FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA058870 Approved Golgi apparatus
Plasma membrane Tissue enhanced Tissue enriched 10 cerebral cortex: 57.0 parathyroid gland: 5.5 ATIC AICARFT, IMPCHASE, PURH ENSG00000138363 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase 2 215311817-215349773 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB013462, HPA021012 Supported Validated Plasma membrane
Cytosol Liver cancer:1.99e-7 (unfavourable), Renal cancer:8.77e-4 (unfavourable) Expressed in all Expressed in all placenta,rectum: 44.5 ATP1A1 ENSG00000163399 ATPase, Na+/K+ transporting, alpha 1 polypeptide 1 116372668-116410261 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB018702, CAB069993 Supported Renal cancer:8.98e-8 (favourable), Liver cancer:1.42e-4 (unfavourable), Urothelial cancer:4.01e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 2441.5 ATP2C1 ATP2C1A, BCPM, KIAA1347, PMR1, SPCA1 ENSG00000017260 ATPase, Ca++ transporting, type 2C, member 1 3 130850595-131016712 Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB010207, HPA035116, HPA069684 Supported Validated Golgi apparatus Liver cancer:5.06e-6 (unfavourable), Pancreatic cancer:1.52e-4 (unfavourable), Renal cancer:1.55e-4 (favourable) Expressed in all Expressed in all prostate: 136.8 ATP4A ATP6A ENSG00000105675 ATPase, H+/K+ exchanging, alpha polypeptide 19 35550043-35563658 Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA039154 Supported Tissue enriched Tissue enriched 250 stomach: 537.7 pancreas: 2.1 ATP6V1B2 ATP6B2, HO57, VATB, Vma2, VPP3 ENSG00000147416 ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B2 8 20197367-20226819 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Transporters Evidence at protein level HPA008147 Supported Supported Vesicles Renal cancer:8.41e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 305.1 AVPR1A AVPR1 ENSG00000166148 Arginine vasopressin receptor 1A 12 63142759-63150942 FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins Evidence at protein level Mixed Tissue enhanced adrenal gland: 78.3 adipose tissue: 19.9 AVPR1B AVPR3 ENSG00000198049 Arginine vasopressin receptor 1B 1 206109692-206117699 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at transcript level Tissue enhanced Not detected stomach: 0.3 AVPR2 DIR, DIR3, V2R ENSG00000126895 Arginine vasopressin receptor 2 X 153902531-153907166 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level HPA046678 Approved Mixed Tissue enhanced adipose tissue: 5.8 heart muscle,kidney: 2.8 BCHE CHE1, CHE2, E1 ENSG00000114200 Butyrylcholinesterase 3 165772904-165837472 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA001560 Supported Head and neck cancer:1.06e-4 (unfavourable) Group enriched Tissue enhanced liver: 264.1 endometrium: 66.8 BCL2 Bcl-2, PPP1R50 ENSG00000171791 B-cell CLL/lymphoma 2 18 63123346-63320128 Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB000003, HPA055295 Supported Supported Nucleoplasm
Nuclear membrane Renal cancer:1.29e-8 (favourable), Cervical cancer:5.13e-5 (favourable), Thyroid cancer:2.47e-4 (unfavourable) Expressed in all Tissue enhanced thyroid gland: 69.2 parathyroid gland: 34.6 BCR ALL, BCR1, CML, D22S11, D22S662, PHL ENSG00000186716 Breakpoint cluster region 22 23179704-23318037 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level CAB010421, CAB018545, HPA038337 Approved Approved Nucleoplasm
Cytosol Renal cancer:9.15e-10 (favourable) Expressed in all Expressed in all cerebral cortex: 48.5 BDKRB2 BK-2 ENSG00000168398 Bradykinin receptor B2 14 96204679-96244166 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA050841 Approved Mixed Mixed gallbladder: 32.6 BGLAP OCN ENSG00000242252 Bone gamma-carboxyglutamate (gla) protein 1 156241962-156243321 FDA approved drug targets, Predicted secreted proteins Evidence at protein level Mixed Mixed skin: 2.1 BLVRB FLR, SDR43U1 ENSG00000090013 Biliverdin reductase B 19 40447789-40465840 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA041698, HPA041937 Supported Supported Nucleoplasm
Plasma membrane
Cytosol Pancreatic cancer:3.90e-4 (unfavourable) Expressed in all Expressed in all bone marrow: 339.1 BRAF BRAF1 ENSG00000157764 B-Raf proto-oncogene, serine/threonine kinase 7 140719327-140924764 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA001328, CAB004552, HPA071048 Approved Approved Vesicles
Cytosol Expressed in all Expressed in all testis: 41.6 BTK AGMX1, ATK, IMD1, PSCTK1, XLA ENSG00000010671 Bruton agammaglobulinemia tyrosine kinase X 101349447-101390796 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA001198, HPA002028, CAB016689 Supported Supported Vesicles Expressed in all Tissue enhanced lymph node: 66.0;tonsil: 73.6 spleen: 53.6 C3 ARMD9, C3a, C3b, CPAMD1 ENSG00000125730 Complement component 3 19 6677704-6730562 Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA003563, CAB004209, HPA020432 Supported Renal cancer:1.09e-5 (unfavourable), Liver cancer:8.11e-4 (favourable) Expressed in all Expressed in all liver: 2484.3 C4A C4, C4A2, C4A3, C4A4, C4A6, C4B, C4S, CO4, CPAMD2, RG ENSG00000244731 Complement component 4A (Rodgers blood group) 6 31982024-32002681 Blood group antigen proteins, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB009811, CAB032603, HPA046356, HPA048287, HPA050103 Approved Tissue enhanced Tissue enhanced liver: 46.2 thyroid gland: 28.2 C4B C4B1, C4B3, C4F, CH, CO4, CPAMD3 ENSG00000224389 Complement component 4B (Chido blood group) 6 32014762-32035418 Blood group antigen proteins, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA046356, HPA048287, HPA050103 Approved Tissue enhanced Tissue enhanced adrenal gland: 59.8;liver: 65.6 kidney: 18.4 C5 C5a, C5b, CPAMD4 ENSG00000106804 Complement component 5 9 120952335-121050276 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA029339 Uncertain Liver cancer:9.43e-4 (favourable) Tissue enriched Tissue enriched 21 liver: 225.4 lung: 10.5 CA1 Car1 ENSG00000133742 Carbonic anhydrase I 8 85327608-85379014 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA006558, CAB025790 Supported Group enriched Group enriched 31 bone marrow: 1219.6;colon: 1039.5;rectum: 2348.0 smooth muscle: 49.1 CA14 ENSG00000118298 Carbonic anhydrase XIV 1 150257159-150265078 Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA008482 Approved Approved Plasma membrane Group enriched Tissue enhanced cerebral cortex: 10.6;seminal vesicle: 21.1 skeletal muscle: 9.4 CA2 CA-II, CAII, Car2 ENSG00000104267 Carbonic anhydrase II 8 85463852-85481493 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA001550, CAB010102 Supported Renal cancer:5.57e-6 (favourable) Expressed in all Tissue enhanced colon: 613.9;rectum: 636.0;stomach: 922.7 kidney: 305.6 CA3 CAIII, Car3 ENSG00000164879 Carbonic anhydrase III 8 85373436-85449040 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004967, HPA021775, HPA026700 Supported Breast cancer:4.24e-6 (favourable) Group enriched Tissue enriched 16 skeletal muscle: 1839.1 prostate: 112.8 CA4 CAIV, Car4, RP17 ENSG00000167434 Carbonic anhydrase IV 17 60149936-60170899 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA011089, HPA017258 Approved Supported Vesicles Mixed Tissue enhanced colon: 258.2;rectum: 183.7 adipose tissue: 88.6 CA7 ENSG00000168748 Carbonic anhydrase VII 16 66844379-66854153 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA047237 Uncertain Tissue enhanced Tissue enhanced colon: 55.7;rectum: 51.1 small intestine: 10.9 CACNA1A APCA, CACNL1A4, Cav2.1, EA2, FHM, HPCA, MHP, MHP1, SCA6 ENSG00000141837 Calcium channel, voltage-dependent, P/Q type, alpha 1A subunit 19 13206442-13623990 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA064258 Supported Approved Nucleoplasm
Golgi apparatus
Vesicles Pancreatic cancer:4.32e-4 (favourable) Mixed Tissue enhanced cerebral cortex: 18.1 stomach: 6.4 CACNA1B CACNL1A5, CACNN, Cav2.2 ENSG00000148408 Calcium channel, voltage-dependent, N type, alpha 1B subunit 9 137877789-138124624 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA044347 Uncertain Tissue enhanced Group enriched 8 adrenal gland: 3.7;cerebral cortex: 14.9;fallopian tube: 4.8;testis: 7.6 prostate: 1.0 CACNA1C CACH2, CACN2, CACNL1A1, Cav1.2, CCHL1A1, LQT8, TS ENSG00000151067 Calcium channel, voltage-dependent, L type, alpha 1C subunit 12 1970786-2697950 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA039796 Supported Mixed Tissue enhanced smooth muscle: 30.9 endometrium: 26.2 CACNA1D CACH3, CACN4, CACNL1A2, Cav1.3, CCHL1A2 ENSG00000157388 Calcium channel, voltage-dependent, L type, alpha 1D subunit 3 53494656-53813733 Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA020215 Uncertain Approved Nuclear membrane Renal cancer:8.34e-8 (favourable) Mixed Mixed fallopian tube: 13.7 CACNA1F AIED, Cav1.4, CORDX3, CSNB2, CSNB2A, CSNBX2, JM8, JMC8, OA2 ENSG00000102001 Calcium channel, voltage-dependent, L type, alpha 1F subunit X 49205063-49233371 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level Not detected Mixed lymph node: 1.6 CACNA1G Cav3.1, NBR13 ENSG00000006283 Calcium channel, voltage-dependent, T type, alpha 1G subunit 17 50561068-50627474 FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA004714 Uncertain Mixed Tissue enhanced cerebral cortex: 10.6;cervix, uterine: 8.5 endometrium: 5.2 CACNA1H Cav3.2 ENSG00000196557 Calcium channel, voltage-dependent, T type, alpha 1H subunit 16 1153241-1221771 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA039125 Approved Approved Nucleoplasm
Vesicles Renal cancer:1.78e-5 (unfavourable), Pancreatic cancer:3.12e-5 (favourable) Expressed in all Tissue enhanced ovary: 50.6 seminal vesicle: 46.9 CACNA1I Cav3.3 ENSG00000100346 Calcium channel, voltage-dependent, T type, alpha 1I subunit 22 39570753-39689737 FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level Tissue enhanced Tissue enhanced cerebral cortex: 4.7;thyroid gland: 2.7 adrenal gland: 2.3 CACNA1S CACNL1A3, Cav1.1, HOKPP, hypoPP, MHS5 ENSG00000081248 Calcium channel, voltage-dependent, L type, alpha 1S subunit 1 201039512-201112566 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level CAB009507, HPA048892, HPA056815 Supported Tissue enhanced Tissue enriched 34 skeletal muscle: 103.0 esophagus: 3.0 CACNA2D1 CACNA2, CACNL2A, LINC01112, lncRNA-N3, MHS3 ENSG00000153956 Calcium channel, voltage-dependent, alpha 2/delta subunit 1 7 81946444-82443798 FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA008213, HPA008621 Supported Renal cancer:1.16e-4 (unfavourable) Mixed Mixed cerebral cortex: 35.5 CACNA2D2 KIAA0558 ENSG00000007402 Calcium channel, voltage-dependent, alpha 2/delta subunit 2 3 50362799-50504244 FDA approved drug targets, Predicted intracellular proteins, Transporters Evidence at protein level HPA034771, HPA071829 Approved Approved Vesicles Endometrial cancer:7.62e-5 (unfavourable), Pancreatic cancer:1.21e-4 (favourable) Tissue enhanced Tissue enriched 6 lung: 73.0 testis: 12.4 CACNB1 CACNLB1 ENSG00000067191 Calcium channel, voltage-dependent, beta 1 subunit 17 39173456-39197703 FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA023343 Approved Endometrial cancer:3.80e-4 (unfavourable) Mixed Group enriched 6 cerebral cortex: 46.9;skeletal muscle: 108.5 skin: 12.3 CACNB2 CACNLB2, MYSB ENSG00000165995 Calcium channel, voltage-dependent, beta 2 subunit 10 18140677-18541869 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Transporters Evidence at protein level HPA035325, HPA035326 Uncertain Renal cancer:3.56e-5 (favourable) Mixed Mixed cerebral cortex: 26.4 CACNB3 CACNLB3 ENSG00000167535 Calcium channel, voltage-dependent, beta 3 subunit 12 48813794-48828941 FDA approved drug targets, Predicted intracellular proteins, Transporters Evidence at protein level HPA059515 Approved Golgi apparatus
Vesicles Mixed Mixed endometrium: 39.8 CACNB4 EJM4 ENSG00000182389 Calcium channel, voltage-dependent, beta 4 subunit 2 151832776-152099079 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transporters Evidence at protein level HPA015601 Approved Mixed Tissue enhanced cerebral cortex: 34.8 skin: 11.2 CACNG1 CACNLG ENSG00000108878 Calcium channel, voltage-dependent, gamma subunit 1 17 67044590-67056797 FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level Tissue enhanced Tissue enriched 25 skeletal muscle: 113.5 esophagus: 4.4 CALY CALCYON, DRD1IP, NSG3 ENSG00000130643 Calcyon neuron-specific vesicular protein 10 133324072-133336935 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA042283 Uncertain Pancreatic cancer:3.54e-4 (favourable) Group enriched Group enriched 13 adrenal gland: 23.6;cerebral cortex: 77.3 testis: 3.8 CAMLG CAML, GET2 ENSG00000164615 Calcium modulating ligand 5 134738501-134752160 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA052636, HPA056472 Approved Approved Nucleus
Nucleoli
Vesicles Renal cancer:1.09e-5 (unfavourable) Expressed in all Expressed in all testis: 99.0 CARTPT CART ENSG00000164326 CART prepropeptide 5 71719163-71721048 FDA approved drug targets, Predicted secreted proteins Evidence at protein level HPA046278 Uncertain Stomach cancer:4.36e-4 (unfavourable) Tissue enriched Tissue enriched 8 adrenal gland: 133.2 cerebral cortex: 17.4 CASR FHH, GPRC2A, HHC, HHC1, NSHPT ENSG00000036828 Calcium-sensing receptor 3 122183683-122286503 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA039686, HPA050335 Supported Tissue enriched Tissue enriched 60 parathyroid gland: 1627.2 kidney: 27.0 CAT ENSG00000121691 Catalase 11 34438925-34472062 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB001515, HPA051282, HPA055838 Supported Supported Vesicles
Cytosol Renal cancer:1.96e-8 (favourable), Liver cancer:9.67e-4 (favourable) Expressed in all Expressed in all liver: 624.4 CCKAR ENSG00000163394 Cholecystokinin A receptor 4 26481400-26490462 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level Mixed Group enriched 9 gallbladder: 47.3;stomach: 14.9 tonsil: 3.2 CCKBR ENSG00000110148 Cholecystokinin B receptor 11 6259736-6272127 Cancer-related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Tissue enriched Group enriched 14 cerebral cortex: 13.7;pancreas: 5.4;stomach: 16.1 prostate: 0.8 CCL2 GDCF-2, HC11, MCAF, MCP-1, MCP1, MGC9434, SCYA2, SMC-CF ENSG00000108691 Chemokine (C-C motif) ligand 2 17 34255218-34257203 Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB013676, HPA019163 Approved Approved Golgi apparatus
Vesicles Renal cancer:4.51e-4 (unfavourable) Expressed in all Expressed in all gallbladder: 412.4 CCND1 BCL1, D11S287E, PRAD1, U21B31 ENSG00000110092 Cyclin D1 11 69641087-69654474 Cancer-related genes, Disease related genes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level CAB000024, HPA027802 Uncertain Supported Nucleoplasm Pancreatic cancer:1.96e-4 (unfavourable), Head and neck cancer:5.51e-4 (unfavourable) Expressed in all Tissue enhanced parathyroid gland: 335.1 skin: 140.9 CCR5 CC-CKR-5, CD195, CKR-5, CKR5, CMKBR5, IDDM22 ENSG00000160791 Chemokine (C-C motif) receptor 5 (gene/pseudogene) 3 46370854-46376206 CD markers, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level Endometrial cancer:7.42e-5 (favourable), Head and neck cancer:9.33e-5 (favourable) Expressed in all Mixed appendix: 20.9 CD19 ENSG00000177455 CD19 molecule 16 28931939-28939346 CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level CAB016110 Supported Mixed Group enriched 11 appendix: 38.8;lymph node: 85.0;spleen: 48.2;tonsil: 70.8 urinary bladder: 5.7 CD2 SRBC ENSG00000116824 CD2 molecule 1 116754385-116769228 CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB002430, HPA003883 Supported Renal cancer:4.82e-6 (unfavourable), Endometrial cancer:1.69e-5 (favourable), Melanoma:3.97e-5 (favourable), Head and neck cancer:7.46e-5 (favourable), Cervical cancer:1.47e-4 (favourable), Breast cancer:4.36e-4 (favourable), Ovarian cancer:7.72e-4 (favourable) Expressed in all Tissue enhanced lymph node: 132.9 tonsil: 73.5 CD247 CD3H, CD3Q, CD3Z ENSG00000198821 CD247 molecule 1 167430640-167518610 CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level CAB004651, HPA008750 Supported Endometrial cancer:8.63e-6 (favourable), Renal cancer:9.94e-6 (unfavourable), Head and neck cancer:3.98e-4 (favourable), Breast cancer:9.12e-4 (favourable) Mixed Tissue enhanced lymph node: 66.0;spleen: 49.4 tonsil: 34.9 CD33 FLJ00391, p67, SIGLEC-3, SIGLEC3 ENSG00000105383 CD33 molecule 19 51225064-51243860 CD markers, FDA approved drug targets, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB011442, HPA035832, HPA064807 Approved Supported Nucleus
Plasma membrane Mixed Tissue enhanced spleen: 33.6 bone marrow: 20.9 CD3D T3D ENSG00000167286 CD3d molecule, delta (CD3-TCR complex) 11 118338954-118342744 CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB013055 Supported Endometrial cancer:1.73e-7 (favourable), Renal cancer:3.07e-5 (unfavourable), Cervical cancer:8.46e-5 (favourable), Head and neck cancer:1.70e-4 (favourable), Breast cancer:3.00e-4 (favourable), Urothelial cancer:6.16e-4 (favourable) Expressed in all Tissue enhanced lymph node: 202.6;tonsil: 124.1 appendix: 90.4 CD3E ENSG00000198851 CD3e molecule, epsilon (CD3-TCR complex) 11 118304545-118316175 CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level CAB000010, HPA040957, HPA043955, CAB072863, CAB072864 Supported Endometrial cancer:2.30e-6 (favourable), Renal cancer:1.12e-5 (unfavourable), Melanoma:1.18e-4 (favourable), Head and neck cancer:1.32e-4 (favourable), Cervical cancer:1.62e-4 (favourable), Breast cancer:1.72e-4 (favourable) Expressed in all Tissue enhanced lymph node: 203.4;tonsil: 118.2 appendix: 97.3 CD3G ENSG00000160654 CD3g molecule, gamma (CD3-TCR complex) 11 118344344-118355161 CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB017520, HPA038494 Supported Renal cancer:9.33e-5 (unfavourable), Cervical cancer:2.61e-4 (favourable), Head and neck cancer:3.00e-4 (favourable), Breast cancer:6.33e-4 (favourable) Mixed Tissue enhanced lymph node: 31.8;tonsil: 19.7 spleen: 16.3 CD4 ENSG00000010610 CD4 molecule 12 6786858-6820808 CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB000011, HPA004252, HPA004472, CAB068180 Supported Supported Plasma membrane Endometrial cancer:2.16e-4 (favourable), Renal cancer:7.45e-4 (unfavourable) Expressed in all Tissue enhanced parathyroid gland: 538.7 spleen: 224.0 CD44 CD44R, CSPG8, HCELL, IN, MC56, MDU2, MDU3, MIC4, Pgp1 ENSG00000026508 CD44 molecule (Indian blood group) 11 35138870-35232402 Blood group antigen proteins, Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB000112, CAB000316, HPA005785 Supported Validated Golgi apparatus
Plasma membrane Renal cancer:1.78e-8 (unfavourable) Expressed in all Expressed in all skin: 505.8 CD52 CDW52 ENSG00000169442 CD52 molecule 1 26317957-26320523 Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins Evidence at protein level Breast cancer:1.85e-5 (favourable), Endometrial cancer:2.06e-4 (favourable), Head and neck cancer:4.45e-4 (favourable), Renal cancer:5.85e-4 (unfavourable) Expressed in all Tissue enriched 34 epididymis: 43067.6 lymph node: 1271.7 CD80 B7-1, B7.1, CD28LG, CD28LG1 ENSG00000121594 CD80 molecule 3 119524293-119559602 CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB025368, HPA050092 Supported Mixed Tissue enhanced appendix: 7.4;lymph node: 6.8;tonsil: 6.1 spleen: 4.6 CD86 B7-2, B7.2, CD28LG2 ENSG00000114013 CD86 molecule 3 122055366-122121139 CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB004319 Uncertain Renal cancer:9.83e-5 (unfavourable) Expressed in all Tissue enhanced appendix: 49.1 spleen: 32.9 CDK4 PSK-J3 ENSG00000135446 Cyclin-dependent kinase 4 12 57747727-57756013 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA006024, CAB069405 Approved Supported Nucleus
Nuclear membrane
Nucleoli
Cytosol Liver cancer:2.09e-7 (unfavourable), Renal cancer:3.15e-5 (unfavourable) Expressed in all Expressed in all endometrium: 120.2 CDK6 PLSTIRE ENSG00000105810 Cyclin-dependent kinase 6 7 92604921-92836594 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA002637, CAB004363 Supported Supported Nucleoplasm
Cytosol Pancreatic cancer:3.86e-6 (unfavourable), Urothelial cancer:2.33e-5 (unfavourable) Expressed in all Mixed parathyroid gland: 33.5 CES1 CEH, CES1A1, CES1A2, CES2, HMSE, HMSE1, SES1 ENSG00000198848 Carboxylesterase 1 16 55802851-55833337 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA012023, HPA046717 Supported Validated Endoplasmic reticulum Urothelial cancer:9.92e-4 (unfavourable) Tissue enriched Group enriched 7 gallbladder: 400.5;liver: 1099.6;lung: 229.6 adipose tissue: 79.7 CFTR ABC35, ABCC7, CF, CFTR/MRP, dJ760C5.1, MRP7, TNR-CFTR ENSG00000001626 Cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) 7 117465784-117715971 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB001951, HPA021939 Supported Liver cancer:9.44e-4 (unfavourable) Tissue enhanced Tissue enhanced gallbladder: 89.6;rectum: 50.1 colon: 47.0 CHD1 ENSG00000153922 Chromodomain helicase DNA binding protein 1 5 98853985-98928957 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA022236 Approved Supported Nucleus
Nucleoli fibrillar center Renal cancer:7.25e-6 (unfavourable) Expressed in all Expressed in all bone marrow: 44.4 CHRM1 ENSG00000168539 Cholinergic receptor, muscarinic 1 11 62908679-62921807 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA014101, CAB022366 Supported Approved Nucleus
Cytosol Tissue enriched Group enriched 6 cerebral cortex: 40.0;prostate: 40.1;salivary gland: 11.1 breast: 4.7 CHRM2 ENSG00000181072 Cholinergic receptor, muscarinic 2 7 136868669-137020255 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level CAB022338, HPA029795 Approved Tissue enhanced Tissue enhanced gallbladder: 18.4;heart muscle: 26.7;smooth muscle: 13.6 urinary bladder: 6.1 CHRM3 ENSG00000133019 Cholinergic receptor, muscarinic 3 1 239386565-239915452 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA024106, HPA048036 Approved Supported Plasma membrane Mixed Tissue enhanced cerebral cortex: 15.7 esophagus: 8.5 CHRM4 ENSG00000180720 Cholinergic receptor, muscarinic 4 11 46385098-46386608 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level CAB022444, HPA072083 Uncertain Uncertain Nucleus
Golgi apparatus Mixed Tissue enhanced cerebral cortex: 8.1;small intestine: 7.9;spleen: 21.9 testis: 6.9 CHRM5 ENSG00000184984 Cholinergic receptor, muscarinic 5 15 33968720-34067457 FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA013172 Uncertain Not detected Tissue enhanced cerebral cortex: 3.1;testis: 4.1 placenta: 2.5 CHRNA10 ENSG00000129749 Cholinergic receptor, nicotinic, alpha 10 (neuronal) 11 3665587-3671384 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Mixed Tissue enriched 17 skeletal muscle: 16.6 lung: 0.9 CHRNA2 ENSG00000120903 Cholinergic receptor, nicotinic, alpha 2 (neuronal) 8 27459761-27479883 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Tissue enriched Tissue enriched 20 prostate: 43.0 breast: 2.1 CHRNA3 ENSG00000080644 Cholinergic receptor, nicotinic, alpha 3 (neuronal) 15 78593052-78621295 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA029430 Approved Mixed Tissue enriched 7 adrenal gland: 48.2 appendix: 6.5 CHRNA4 BFNC, EBN, EBN1 ENSG00000101204 Cholinergic receptor, nicotinic, alpha 4 (neuronal) 20 63343223-63378401 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB034064 Uncertain Tissue enhanced Tissue enhanced cerebral cortex: 6.8;parathyroid gland: 16.9 liver: 3.7 CHRNA7 ENSG00000175344 Cholinergic receptor, nicotinic, alpha 7 (neuronal) 15 32030488-32172521 FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA029422, CAB033624 Supported Mixed Tissue enhanced adrenal gland: 6.0;small intestine: 6.0 stomach: 3.6 CHRNB2 ENSG00000160716 Cholinergic receptor, nicotinic, beta 2 (neuronal) 1 154567781-154580026 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level Tissue enhanced Tissue enriched 14 cerebral cortex: 22.0 adrenal gland: 1.5 CHRNB4 ENSG00000117971 Cholinergic receptor, nicotinic, beta 4 (neuronal) 15 78624119-78727754 FDA approved drug targets, Predicted membrane proteins Evidence at protein level Tissue enhanced Tissue enhanced adrenal gland: 3.2;testis: 5.3 appendix: 0.9 CKB CKBB ENSG00000166165 Creatine kinase, brain 14 103519659-103523111 Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA001254, CAB047313 Supported Supported Cytosol Renal cancer:4.02e-8 (favourable) Expressed in all Expressed in all cerebral cortex: 476.4 CKM CKMM ENSG00000104879 Creatine kinase, muscle 19 45306414-45322977 Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA047859 Supported Group enriched Tissue enriched 15 skeletal muscle: 23804.3 heart muscle: 1618.7 CKMT1A CKMT1 ENSG00000223572 Creatine kinase, mitochondrial 1A 15 43692886-43699222 Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at protein level HPA043491 Uncertain Mixed Mixed rectum: 75.0 CKMT1B CKMT, CKMT1, UMTCK ENSG00000237289 Creatine kinase, mitochondrial 1B 15 43593054-43604901 Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at protein level HPA043491 Uncertain Endometrial cancer:2.55e-5 (unfavourable) Mixed Tissue enhanced colon: 79.4;rectum: 69.8 duodenum: 64.7 CKMT2 SMTCK ENSG00000131730 Creatine kinase, mitochondrial 2 (sarcomeric) 5 81233285-81266397 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA051880 Approved Mixed Group enriched 21 heart muscle: 672.7;skeletal muscle: 505.4 adrenal gland: 28.1 CLCN2 ClC-2, CLC2, EJM6 ENSG00000114859 Chloride channel, voltage-sensitive 2 3 184346185-184361651 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB009397, HPA014545, HPA024108 Approved Approved Cytosol Liver cancer:4.67e-8 (unfavourable) Expressed in all Mixed testis: 22.0 CNR1 CANN6, CB-R, CB1, CB1A, CB1K5, CNR ENSG00000118432 Cannabinoid receptor 1 (brain) 6 88139864-88166359 FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB005603, HPA042256 Approved Approved Plasma membrane
Actin filaments Tissue enriched Tissue enhanced cerebral cortex: 32.2 adipose tissue: 12.1 CNR2 CB2 ENSG00000188822 Cannabinoid receptor 2 (macrophage) 1 23870526-23913362 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level CAB009719 Uncertain Tissue enriched Group enriched 7 appendix: 3.2;lymph node: 8.8;spleen: 8.1;tonsil: 7.2 bone marrow: 1.0 COMT ENSG00000093010 Catechol-O-methyltransferase 22 19941607-19969975 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA001169, CAB011233 Supported Approved Endoplasmic reticulum
Vesicles Endometrial cancer:3.68e-4 (favourable), Prostate cancer:5.67e-4 (favourable), Renal cancer:9.76e-4 (unfavourable) Expressed in all Expressed in all placenta: 172.0 CPS1 ENSG00000021826 Carbamoyl-phosphate synthase 1, mitochondrial 2 210477682-210679107 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB003781, HPA021400 Supported Approved Nucleoli Liver cancer:6.93e-5 (favourable) Tissue enriched Group enriched 24 duodenum: 241.2;liver: 697.3;small intestine: 147.2 testis: 15.2 CPT1A CPT1, CPT1-L, L-CPT1 ENSG00000110090 Carnitine palmitoyltransferase 1A (liver) 11 68754620-68844410 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA008835 Supported Supported Mitochondria Renal cancer:2.67e-7 (favourable), Breast cancer:3.84e-4 (unfavourable) Expressed in all Expressed in all small intestine: 80.5 CPT2 CPT1, CPTASE ENSG00000157184 Carnitine palmitoyltransferase 2 1 53196429-53214197 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA028201, HPA028202, HPA028214 Supported Supported Nucleoplasm
Nucleoli
Mitochondria Renal cancer:1.46e-12 (favourable), Colorectal cancer:5.27e-4 (favourable) Expressed in all Expressed in all liver: 42.1 CRBN MRT2, MRT2A ENSG00000113851 Cereblon 3 3148992-3179710 Disease related genes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA045910 Approved Approved Nucleoli Expressed in all Expressed in all testis: 86.2 CSF2RA CD116, CSF2R ENSG00000198223 Colony stimulating factor 2 receptor, alpha, low-affinity (granulocyte-macrophage) X 1268800-1310381 Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB016148 Uncertain Cervical cancer:2.38e-5 (favourable), Head and neck cancer:2.81e-4 (favourable), Testis cancer:5.53e-4 (unfavourable) Expressed in all Tissue enhanced placenta: 93.5 appendix: 36.4 CSF2RB CD131, IL3RB, IL5RB ENSG00000100368 Colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage) 22 36913628-36940449 CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA078677 Uncertain Golgi apparatus Head and neck cancer:7.47e-5 (favourable) Expressed in all Tissue enhanced appendix: 92.0 tonsil: 59.3 CSF3R CD114, GCSFR ENSG00000119535 Colony stimulating factor 3 receptor (granulocyte) 1 36466043-36483278 Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB017116, HPA048086 Supported Testis cancer:3.79e-4 (unfavourable), Renal cancer:5.72e-4 (unfavourable) Mixed Tissue enhanced appendix: 215.2;bone marrow: 243.8;placenta: 147.0 spleen: 98.2 CTLA4 CD, CD152, CD28, CELIAC3, GSE, ICOS, IDDM12 ENSG00000163599 Cytotoxic T-lymphocyte-associated protein 4 2 203867786-203873960 CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Head and neck cancer:4.48e-5 (favourable) Mixed Tissue enhanced appendix: 24.2;lymph node: 32.3 tonsil: 15.9 CXCR4 CD184, D2S201E, fusin, HM89, HSY3RR, LESTR, NPY3R, NPYR, NPYY3R ENSG00000121966 Chemokine (C-X-C motif) receptor 4 2 136114349-136118165 Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level Renal cancer:1.41e-7 (unfavourable), Ovarian cancer:2.05e-4 (favourable), Stomach cancer:5.67e-4 (unfavourable) Expressed in all Tissue enhanced bone marrow: 772.9 tonsil: 514.7 CYP11B1 CPN1, CYP11B, FHI, P450C11 ENSG00000160882 Cytochrome P450, family 11, subfamily B, polypeptide 1 8 142872356-142879846 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA049171, HPA056348, HPA057752 Supported Not detected Tissue enriched 936 adrenal gland: 1879.5 testis: 2.0 CYP17A1 CPT7, CYP17, P450C17, S17AH ENSG00000148795 Cytochrome P450, family 17, subfamily A, polypeptide 1 10 102830531-102837533 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA048533 Supported Renal cancer:5.43e-7 (favourable) Tissue enriched Tissue enriched 25 adrenal gland: 4500.7 testis: 180.3 CYP19A1 ARO, ARO1, aromatase, CPV1, CYAR, CYP19, P-450AROM ENSG00000137869 Cytochrome P450, family 19, subfamily A, polypeptide 1 15 51208057-51338610 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB000355, HPA051194 Supported Approved Vesicles Mixed Tissue enriched 14 placenta: 173.9 testis: 12.4 CYP51A1 CP51, CYP51, CYPL1, LDM, P450-14DM, P450L1 ENSG00000001630 Cytochrome P450, family 51, subfamily A, polypeptide 1 7 92112151-92142952 Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041325, HPA043508 Approved Validated Endoplasmic reticulum Cervical cancer:6.12e-4 (unfavourable) Expressed in all Expressed in all testis: 175.2 CYSLTR1 CysLT(1), CysLT1, CYSLT1R ENSG00000173198 Cysteinyl leukotriene receptor 1 X 78271464-78327691 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level HPA010546 Approved Mixed Mixed spleen: 15.1 CYSLTR2 CysLT(2), CYSLT2R ENSG00000152207 Cysteinyl leukotriene receptor 2 13 48653711-48711226 FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA046528 Uncertain Group enriched Tissue enhanced placenta: 36.4;seminal vesicle: 24.8 spleen: 11.6 DBH DBM ENSG00000123454 Dopamine beta-hydroxylase (dopamine beta-monooxygenase) 9 133636360-133659344 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA002130, HPA005960, HPA070789 Supported Supported Vesicles Mixed Tissue enriched 12 adrenal gland: 358.5 epididymis: 30.6 DCK ENSG00000156136 Deoxycytidine kinase 4 70992538-71030914 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA059609, HPA062773 Approved Supported Nucleus Liver cancer:6.90e-7 (unfavourable) Expressed in all Expressed in all lymph node: 95.0 DDC AADC ENSG00000132437 Dopa decarboxylase (aromatic L-amino acid decarboxylase) 7 50458436-50565457 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA017742 Supported Approved Actin filaments Mixed Tissue enhanced duodenum: 159.5;kidney: 318.7;small intestine: 184.3 adrenal gland: 64.1 DDR2 NTRKR3, TKT, TYRO10 ENSG00000162733 Discoidin domain receptor tyrosine kinase 2 1 162631373-162787400 CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA070112 Supported Plasma membrane
Actin filaments Renal cancer:1.73e-7 (unfavourable) Expressed in all Mixed adrenal gland: 94.0 DHFR ENSG00000228716 Dihydrofolate reductase 5 80626228-80654983 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level CAB037129, HPA051465 Uncertain Supported Mitochondria Expressed in all Mixed lymph node: 50.1 DHODH ENSG00000102967 Dihydroorotate dehydrogenase (quinone) 16 72008588-72027664 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA010123, HPA011942 Approved Supported Nucleoplasm
Mitochondria Expressed in all Mixed liver: 23.7 DNMT1 CXXC9, DNMT, MCMT ENSG00000130816 DNA (cytosine-5-)-methyltransferase 1 19 10133345-10231286 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA002694, CAB005876 Supported Validated Nucleoplasm Liver cancer:1.46e-4 (unfavourable) Expressed in all Expressed in all placenta: 51.2 DPEP1 ENSG00000015413 Dipeptidase 1 (renal) 16 89613308-89638456 Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at protein level HPA009426, HPA012783 Supported Approved Nucleus
Cell Junctions Renal cancer:6.84e-4 (favourable) Tissue enriched Tissue enhanced kidney: 262.3;small intestine: 426.5 pancreas: 92.8 DPP4 ADCP2, CD26, DPPIV ENSG00000197635 Dipeptidyl-peptidase 4 2 161992241-162074542 CD markers, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB045970 Supported Renal cancer:1.35e-6 (favourable), Prostate cancer:1.98e-4 (unfavourable), Thyroid cancer:4.99e-4 (favourable) Expressed in all Tissue enhanced parathyroid gland: 542.0 placenta: 167.8 DRD1 ENSG00000184845 Dopamine receptor D1 5 175440039-175444208 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA013393 Uncertain Mixed Tissue enhanced cerebral cortex: 8.0 prostate: 1.6 DRD2 ENSG00000149295 Dopamine receptor D2 11 113409615-113475691 FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA015691 Supported Mixed Tissue enriched 5 adrenal gland: 11.3 smooth muscle: 2.2 DRD3 ENSG00000151577 Dopamine receptor D3 3 114128652-114199407 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level Not detected Tissue enriched 13 testis: 1.3 lymph node: 0.1 DRD4 ENSG00000069696 Dopamine receptor D4 11 637293-640706 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level Mixed Not detected skin: 0.3 DRD5 DRD1B, DRD1L2 ENSG00000169676 Dopamine receptor D5 4 9781680-9784009 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA048930 Supported Not detected Tissue enhanced appendix: 1.8;cerebral cortex: 2.0;stomach: 3.7 testis: 0.8 EDNRA ENSG00000151617 Endothelin receptor type A 4 147480917-147544954 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA013774, CAB018957 Uncertain Renal cancer:1.50e-7 (unfavourable), Stomach cancer:3.93e-4 (unfavourable) Expressed in all Tissue enhanced seminal vesicle: 145.4 cervix, uterine: 82.6 EDNRB ETB, HSCR, HSCR2 ENSG00000136160 Endothelin receptor type B 13 77895481-77919768 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB017842, HPA027546 Approved Approved Plasma membrane
Cytosol Renal cancer:7.20e-5 (favourable) Group enriched Tissue enhanced placenta: 178.8 cerebral cortex: 89.1 EGF ENSG00000138798 Epidermal growth factor 4 109912884-110012266 Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins Evidence at protein level Mixed Tissue enriched 7 kidney: 121.1 pancreas: 18.5 EGFR ERBB, ERBB1 ENSG00000146648 Epidermal growth factor receptor 7 55019021-55256620 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB000035, HPA001200, HPA018530, CAB068186, CAB073534 Supported Validated Plasma membrane Urothelial cancer:2.04e-5 (unfavourable) Expressed in all Tissue enhanced placenta: 97.3 skin: 58.9 ELANE ELA2, HLE, HNE, NE ENSG00000197561 Elastase, neutrophil expressed 19 851014-856247 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB015409, HPA066836 Supported Group enriched Tissue enriched 320 bone marrow: 1202.2 skin: 3.7 EPHA2 ECK ENSG00000142627 EPH receptor A2 1 16124337-16156087 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, RAS pathway related proteins Evidence at protein level HPA066055 Uncertain Vesicles Expressed in all Tissue enhanced esophagus: 87.1 gallbladder: 44.7 EPOR ENSG00000187266 Erythropoietin receptor 19 11377205-11384342 Cancer-related genes, Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA077613 Uncertain Vesicles Pancreatic cancer:3.17e-5 (favourable) Expressed in all Tissue enhanced parathyroid gland: 52.9 thyroid gland: 18.1 ERBB2 CD340, HER-2, HER2, NEU, NGL ENSG00000141736 Erb-b2 receptor tyrosine kinase 2 17 39687914-39730426 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB000043, HPA001060, HPA001338, HPA001383, CAB020416, CAB062555 Approved Supported Plasma membrane
Cytosol Renal cancer:2.41e-14 (favourable), Endometrial cancer:8.99e-8 (unfavourable), Pancreatic cancer:9.17e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 122.9 ERBB4 ALS19, HER4 ENSG00000178568 Erb-b2 receptor tyrosine kinase 4 2 211375717-212538841 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB000276, HPA012016, CAB025522 Approved Tissue enhanced Tissue enhanced fallopian tube: 17.6 cerebral cortex: 7.6 ESR1 Era, ESR, NR3A1 ENSG00000091831 Estrogen receptor 1 6 151656691-152129619 Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB000037, HPA000449, HPA000450, CAB055099, CAB072858 Supported Approved Nucleus
Vesicles Endometrial cancer:5.47e-7 (favourable) Group enriched Group enriched 8 breast: 37.4;cervix, uterine: 127.3;endometrium: 179.7;fallopian tube: 105.5;smooth muscle: 75.9 seminal vesicle: 13.5 ESR2 Erb, NR3A2 ENSG00000140009 Estrogen receptor 2 (ER beta) 14 64084232-64338112 Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB022544 Approved Nucleoplasm Not detected Tissue enhanced testis: 10.5 adrenal gland: 6.3 ESRRG NR3B3 ENSG00000196482 Estrogen-related receptor gamma 1 216503246-217137755 FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA044678 Uncertain Approved Nucleus Renal cancer:1.13e-11 (favourable) Mixed Tissue enhanced parathyroid gland: 76.1 kidney: 31.1 F10 ENSG00000126218 Coagulation factor X 13 113122814-113149529 Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level Pancreatic cancer:1.82e-5 (favourable), Renal cancer:5.14e-5 (unfavourable) Tissue enriched Tissue enhanced liver: 68.0 cervix, uterine: 51.6 F11 FXI ENSG00000088926 Coagulation factor XI 4 186265945-186288806 Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA039808 Approved Vesicles Liver cancer:3.29e-5 (favourable) Tissue enriched Tissue enhanced liver: 179.3 kidney: 44.4 F2 ENSG00000180210 Coagulation factor II (thrombin) 11 46719180-46739506 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB016780, CAB018650, HPA051476, HPA054698 Supported Renal cancer:6.75e-12 (unfavourable) Tissue enriched Tissue enriched 1471 liver: 627.1 testis: 0.4 F2R CF2R, PAR-1, PAR1, TR ENSG00000181104 Coagulation factor II (thrombin) receptor 5 76716043-76735781 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB008973, CAB012962 Approved Renal cancer:2.21e-7 (unfavourable) Expressed in all Expressed in all spleen: 95.4 F5 ENSG00000198734 Coagulation factor V (proaccelerin, labile factor) 1 169514166-169586588 Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA002036 Uncertain Approved Golgi apparatus Stomach cancer:3.39e-4 (unfavourable) Tissue enriched Group enriched 11 gallbladder: 28.5;liver: 93.7;placenta: 67.7 fallopian tube: 5.8 F7 ENSG00000057593 Coagulation factor VII (serum prothrombin conversion accelerator) 13 113105788-113120681 Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level Tissue enriched Tissue enriched 44 liver: 65.2 testis: 1.4 F8 DXS1253E, F8C, FVIII, HEMA ENSG00000185010 Coagulation factor VIII, procoagulant component X 154835788-155026940 Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB018777 Supported Expressed in all Expressed in all lung: 23.4 F9 FIX ENSG00000101981 Coagulation factor IX X 139530758-139563458 Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level Liver cancer:6.69e-4 (favourable) Tissue enriched Tissue enriched 2286 liver: 364.7 kidney: 0.1 FADS1 D5D, FADS6, FADSD5, LLCDL1, TU12 ENSG00000149485 Fatty acid desaturase 1 11 61799625-61829318 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA042705 Approved Renal cancer:1.95e-9 (unfavourable), Urothelial cancer:1.33e-4 (unfavourable), Thyroid cancer:2.79e-4 (unfavourable) Expressed in all Expressed in all adrenal gland: 89.6 FADS2 D6D, DES6, FADSD6, LLCDL2, SLL0262, TU13 ENSG00000134824 Fatty acid desaturase 2 11 61792980-61867354 Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA006741 Approved Renal cancer:1.00e-7 (unfavourable), Urothelial cancer:3.42e-4 (unfavourable) Expressed in all Expressed in all adrenal gland: 416.6 FASN FAS, SDR27X1 ENSG00000169710 Fatty acid synthase 17 82078333-82098332 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB005192, HPA006461, CAB015417, HPA056108 Supported Validated Plasma membrane
Cytosol Cervical cancer:1.42e-5 (unfavourable), Renal cancer:7.16e-5 (unfavourable) Expressed in all Expressed in all adipose tissue: 283.6 FCER1A FCE1A ENSG00000179639 Fc fragment of IgE, high affinity I, receptor for; alpha polypeptide 1 159289714-159308224 FDA approved drug targets, Predicted membrane proteins Evidence at protein level CAB022102, HPA036051, CAB055526 Approved Renal cancer:1.20e-4 (favourable) Expressed in all Mixed skin: 39.9 FCER1G ENSG00000158869 Fc fragment of IgE, high affinity I, receptor for; gamma polypeptide 1 161215234-161220699 FDA approved drug targets, Predicted membrane proteins Evidence at protein level CAB022108, HPA026872 Supported Renal cancer:1.83e-6 (unfavourable) Expressed in all Expressed in all spleen: 470.3 FCGR1A CD64, CD64A ENSG00000150337 Fc fragment of IgG, high affinity Ia, receptor (CD64) 1 149782671-149792518 CD markers, FDA approved drug targets, Predicted membrane proteins Evidence at protein level Renal cancer:4.83e-8 (unfavourable) Tissue enhanced Tissue enhanced appendix: 50.0;epididymis: 90.7 placenta: 38.3 FCGR1B CD64b ENSG00000198019 Fc fragment of IgG, high affinity Ib, receptor (CD64) 1 121087345-121096310 FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at transcript level Tissue enhanced Tissue enhanced appendix: 28.1;epididymis: 61.7 placenta: 17.2 FCGR2A CD32, CD32A, CDw32, FCG2, FCGR2, FCGR2A1, IGFR2 ENSG00000143226 Fc fragment of IgG, low affinity IIa, receptor (CD32) 1 161505430-161524013 CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA010718, HPA014730 Supported Renal cancer:6.49e-7 (unfavourable) Expressed in all Tissue enhanced appendix: 151.6;placenta: 159.2 lung: 118.4 FCGR2B CD32, CD32B, FCG2, FCGR2 ENSG00000072694 Fc fragment of IgG, low affinity IIb, receptor (CD32) 1 161663147-161678654 Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level CAB007796, HPA014730 Supported Renal cancer:8.82e-4 (unfavourable) Mixed Tissue enriched 16 placenta: 571.2 adipose tissue: 36.3 FCGR3A CD16, CD16a, FCG3, FCGR3 ENSG00000203747 Fc fragment of IgG, low affinity IIIa, receptor (CD16a) 1 161541759-161550737 CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB032435, HPA055431 Supported Renal cancer:3.22e-6 (unfavourable) Expressed in all Expressed in all spleen: 427.3 FCGR3B CD16, CD16b, FCG3, FCGR3 ENSG00000162747 Fc fragment of IgG, low affinity IIIb, receptor (CD16b) 1 161623196-161631963 CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Mixed Tissue enhanced appendix: 120.2;spleen: 116.8 urinary bladder: 37.8 FDPS ENSG00000160752 Farnesyl diphosphate synthase 1 155308748-155320666 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA028200 Approved Approved Nucleoplasm
Cytosol Liver cancer:7.35e-4 (unfavourable) Expressed in all Expressed in all liver: 186.1 FFAR1 FFA1R, GPR40 ENSG00000126266 Free fatty acid receptor 1 19 35351552-35353862 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level Tissue enriched Tissue enhanced bone marrow: 1.9 ovary: 1.2 FGA ENSG00000171560 Fibrinogen alpha chain 4 154583126-154590766 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB016776, HPA051370, HPA064755 Supported Renal cancer:4.23e-6 (unfavourable), Liver cancer:7.33e-4 (favourable) Tissue enriched Tissue enriched 246 liver: 9252.8 stomach: 37.6 FGF1 AFGF, ECGF, ECGF-beta, ECGFA, ECGFB, FGF-alpha, FGFA, GLIO703, HBGF1 ENSG00000113578 Fibroblast growth factor 1 (acidic) 5 142592178-142698070 Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level HPA003265, CAB017519 Supported Validated Nucleoplasm Renal cancer:2.59e-5 (favourable), Thyroid cancer:3.45e-5 (favourable) Tissue enriched Tissue enhanced cerebral cortex: 130.3;kidney: 59.1 heart muscle: 32.8 FGF2 FGFB ENSG00000138685 Fibroblast growth factor 2 (basic) 4 122826708-122898236 Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB000125 Approved Supported Nucleoplasm
Nuclear bodies Pancreatic cancer:9.85e-4 (unfavourable) Mixed Mixed adipose tissue: 25.4 FGFR1 BFGFR, CD331, CEK, FLG, FLT2, H2, H3, H4, H5, KAL2, N-SAM ENSG00000077782 Fibroblast growth factor receptor 1 8 38411138-38468834 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB033614, HPA056402, HPA076274 Approved Approved Nucleoli Expressed in all Expressed in all gallbladder: 109.6 FGFR2 BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25 ENSG00000066468 Fibroblast growth factor receptor 2 10 121478334-121598458 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB010886, HPA035305, HPA056562 Uncertain Approved Vesicles Cervical cancer:8.79e-4 (favourable), Head and neck cancer:9.32e-4 (favourable) Expressed in all Mixed skin: 97.5 FGFR3 ACH, CD333, CEK2, JTK4 ENSG00000068078 Fibroblast growth factor receptor 3 4 1793307-1808872 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB004231, HPA067204 Supported Supported Endoplasmic reticulum Endometrial cancer:3.77e-4 (unfavourable) Expressed in all Tissue enriched 7 skin: 334.6 cerebral cortex: 49.7 FGFR4 CD334, JTK2 ENSG00000160867 Fibroblast growth factor receptor 4 5 177086886-177098144 Cancer-related genes, CD markers, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB005196, HPA027273, HPA027369, HPA028251 Approved Mixed Tissue enhanced lung: 39.1 duodenum: 22.0 FKBP1A FKBP-12, FKBP1, FKBP12, FKBP12C, PKC12, PPIASE ENSG00000088832 FK506 binding protein 1A, 12kDa 20 1368978-1393172 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB004639, HPA051798, HPA057830 Uncertain Approved Microtubules Liver cancer:3.44e-7 (unfavourable), Renal cancer:6.69e-5 (unfavourable) Expressed in all Expressed in all thyroid gland: 368.4 FLT1 FLT, VEGFR1 ENSG00000102755 Fms-related tyrosine kinase 1 13 28300344-28495128 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level HPA011740, HPA014290, CAB068189, CAB068190 Supported Supported Plasma membrane
Actin filaments Renal cancer:2.19e-4 (unfavourable) Expressed in all Tissue enriched 8 placenta: 617.5 thyroid gland: 81.7 FLT3 CD135, FLK2, STK1 ENSG00000122025 Fms-related tyrosine kinase 3 13 28003274-28100592 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA047539 Approved Endoplasmic reticulum Tissue enhanced Tissue enhanced lymph node: 7.1;spleen: 7.8 appendix: 4.0 FLT4 PCL, VEGFR3 ENSG00000037280 Fms-related tyrosine kinase 4 5 180601506-180649624 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB000099 Supported Nuclear speckles
Plasma membrane
Cell Junctions Expressed in all Mixed spleen: 18.6 FN1 CIG, FINC, GFND2, LETS, MSF ENSG00000115414 Fibronectin 1 2 215360440-215436172 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB000126, HPA027066 Supported Renal cancer:3.44e-8 (unfavourable), Stomach cancer:8.82e-5 (unfavourable), Urothelial cancer:3.33e-4 (unfavourable) Expressed in all Tissue enhanced placenta: 4245.7 lung: 1168.8 FOLH1 FOLH, GCP2, GCPII, NAALAD1, NAALAdase, PSM, PSMA ENSG00000086205 Folate hydrolase (prostate-specific membrane antigen) 1 11 49146635-49208670 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB001451, HPA010593 Supported Renal cancer:1.30e-6 (unfavourable), Endometrial cancer:5.24e-5 (favourable), Liver cancer:4.25e-4 (favourable) Tissue enriched Group enriched 6 duodenum: 307.0;prostate: 128.9;small intestine: 93.5 cerebral cortex: 31.1 FRK GTK, PTK5, RAK ENSG00000111816 Fyn-related Src family tyrosine kinase 6 115931149-116060758 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB025217, HPA057484 Approved Supported Nucleoplasm
Cytosol Renal cancer:9.66e-7 (favourable) Mixed Mixed kidney: 10.4 FSHR FSHRO, LGR1, ODG1 ENSG00000170820 Follicle stimulating hormone receptor 2 48962157-49154537 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level Not detected Group enriched 9 ovary: 2.5;testis: 4.3 gallbladder,heart muscle: 0.3 FTH1 FHC, FTH, FTHL6, PIG15, PLIF ENSG00000167996 Ferritin, heavy polypeptide 1 11 61959718-61967660 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB008623 Approved Approved Microtubules Renal cancer:5.20e-5 (unfavourable), Head and neck cancer:7.56e-5 (unfavourable), Liver cancer:6.18e-4 (unfavourable) Expressed in all Expressed in all appendix: 5085.0 FTL MGC71996, NBIA3 ENSG00000087086 Ferritin, light polypeptide 19 48965301-48966878 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB020769, HPA041602 Supported Approved Cytosol Renal cancer:4.40e-5 (unfavourable) Expressed in all Expressed in all lung: 8051.2 FXYD2 ATP1G1, HOMG2, MGC12372 ENSG00000137731 FXYD domain containing ion transport regulator 2 11 117800844-117828698 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA064218, HPA068838 Supported Approved Mitochondria Renal cancer:3.23e-9 (favourable) Tissue enriched Group enriched 6 gallbladder: 575.2;kidney: 1428.7;salivary gland: 383.4 pancreas: 134.6 GAA ENSG00000171298 Glucosidase, alpha; acid 17 80101556-80119879 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA026970, HPA029126 Supported Colorectal cancer:7.66e-4 (unfavourable) Expressed in all Expressed in all placenta: 69.4 GABBR1 GPRC3A, hGB1a ENSG00000204681 Gamma-aminobutyric acid (GABA) B receptor, 1 6 29555629-29633976 FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA050483, HPA058459 Uncertain Uncertain Centrosome Renal cancer:3.77e-10 (unfavourable), Pancreatic cancer:2.54e-5 (favourable) Expressed in all Tissue enhanced cerebral cortex: 20.9 spleen: 13.3 GABBR2 GABABR2, GPR51, GPRC3B, HG20 ENSG00000136928 Gamma-aminobutyric acid (GABA) B receptor, 2 9 98288082-98709197 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level HPA013820, HPA031684 Supported Group enriched Tissue enriched 19 cerebral cortex: 88.4 adrenal gland: 4.6 GABRA1 EJM5 ENSG00000022355 Gamma-aminobutyric acid (GABA) A receptor, alpha 1 5 161847191-161899981 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level CAB022502, HPA055746 Supported Tissue enriched Tissue enriched 44 cerebral cortex: 109.1 adrenal gland: 2.4 GABRA2 ENSG00000151834 Gamma-aminobutyric acid (GABA) A receptor, alpha 2 4 46248427-46475230 FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level Tissue enhanced Tissue enriched 6 cerebral cortex: 74.5 epididymis: 13.3 GABRA3 ENSG00000011677 Gamma-aminobutyric acid (GABA) A receptor, alpha 3 X 152166234-152451358 FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA000839 Approved Supported Tissue enriched Tissue enriched 7 cerebral cortex: 28.9 placenta: 4.1 GABRA4 ENSG00000109158 Gamma-aminobutyric acid (GABA) A receptor, alpha 4 4 46918900-46994407 FDA approved drug targets, Predicted membrane proteins Evidence at protein level Not detected Tissue enriched 12 cerebral cortex: 15.1 heart muscle: 1.2 GABRA5 ENSG00000186297 Gamma-aminobutyric acid (GABA) A receptor, alpha 5 15 26866363-26949207 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA077031 Supported Cell Junctions Mixed Tissue enriched 43 cerebral cortex: 82.0 esophagus: 1.8 GABRA6 ENSG00000145863 Gamma-aminobutyric acid (GABA) A receptor, alpha 6 5 161547063-161702593 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA019188, CAB022462, HPA058329 Uncertain Not detected Tissue enhanced testis: 1.2 cerebral cortex: 0.3 GABRB1 ENSG00000163288 Gamma-aminobutyric acid (GABA) A receptor, beta 1 4 46993723-47426444 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA051297 Uncertain Tissue enhanced Tissue enriched 15 cerebral cortex: 19.8 heart muscle: 1.3 GABRB2 ENSG00000145864 Gamma-aminobutyric acid (GABA) A receptor, beta 2 5 161288429-161549044 FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB001964, HPA067632 Supported Tissue enriched Tissue enriched 11 cerebral cortex: 63.0 epididymis: 5.5 GABRB3 ENSG00000166206 Gamma-aminobutyric acid (GABA) A receptor, beta 3 15 26543546-26939539 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level Mixed Tissue enhanced cerebral cortex: 80.1 gallbladder: 21.9 GABRD ENSG00000187730 Gamma-aminobutyric acid (GABA) A receptor, delta 1 2019324-2030751 Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA044371 Supported Uncertain Golgi apparatus
Vesicles Renal cancer:4.12e-8 (unfavourable) Expressed in all Tissue enriched 10 cerebral cortex: 47.4 testis: 4.5 GABRE ENSG00000102287 Gamma-aminobutyric acid (GABA) A receptor, epsilon X 151953124-151974680 FDA approved drug targets, Predicted membrane proteins Evidence at transcript level HPA045918 Uncertain Renal cancer:4.05e-11 (unfavourable) Mixed Tissue enhanced adipose tissue: 10.1 heart muscle: 5.5 GABRG1 ENSG00000163285 Gamma-aminobutyric acid (GABA) A receptor, gamma 1 4 46035769-46124081 FDA approved drug targets, Predicted membrane proteins Evidence at transcript level HPA035622 Approved Tissue enriched Tissue enriched 17 cerebral cortex: 26.1 ovary: 1.5 GABRG2 ENSG00000113327 Gamma-aminobutyric acid (GABA) A receptor, gamma 2 5 162067540-162155536 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level Tissue enhanced Tissue enriched 9 cerebral cortex: 74.3 adrenal gland: 8.2 GABRG3 ENSG00000182256 Gamma-aminobutyric acid (GABA) A receptor, gamma 3 15 26971282-27541991 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA054010 Supported Tissue enhanced Tissue enhanced prostate: 10.6;testis: 16.4 cerebral cortex: 4.2 GABRP ENSG00000094755 Gamma-aminobutyric acid (GABA) A receptor, pi 5 170763350-170814047 FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB014883 Uncertain Cervical cancer:3.37e-4 (favourable) Mixed Expressed in all breast: 186.6 GABRQ THETA ENSG00000268089 Gamma-aminobutyric acid (GABA) A receptor, theta X 152638183-152657534 FDA approved drug targets, Predicted membrane proteins Evidence at transcript level HPA002063 Uncertain Tissue enhanced Tissue enhanced cerebral cortex: 6.6;cervix, uterine: 12.8 adrenal gland: 3.0 GABRR1 ENSG00000146276 Gamma-aminobutyric acid (GABA) A receptor, rho 1 6 89177501-89231278 FDA approved drug targets, Predicted membrane proteins Evidence at protein level Not detected Tissue enriched 6 testis: 1.8 placenta: 0.3 GABRR2 ENSG00000111886 Gamma-aminobutyric acid (GABA) A receptor, rho 2 6 89257208-89315299 FDA approved drug targets, Predicted membrane proteins Evidence at transcript level Not detected Not detected adrenal gland,appendix,cerebral cortex,endometrium,gallbladder,lymph node,skin,spleen,testis,thyroid gland: 0.1 GABRR3 ENSG00000183185 Gamma-aminobutyric acid (GABA) A receptor, rho 3 (gene/pseudogene) 3 97986673-98035304 FDA approved drug targets, Predicted membrane proteins No evidence Not detected Not detected testis: 0.2 GAMT PIG2, TP53I2 ENSG00000130005 Guanidinoacetate N-methyltransferase 19 1397084-1401570 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA051806 Approved Stomach cancer:6.57e-4 (unfavourable) Tissue enriched Expressed in all skeletal muscle: 400.4 GANAB G2AN, GluII, KIAA0088 ENSG00000089597 Glucosidase, alpha; neutral AB 11 62624826-62646726 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA026874, HPA061426 Supported Approved Nuclear membrane
Endoplasmic reticulum
Cytosol Liver cancer:1.27e-5 (unfavourable), Urothelial cancer:9.54e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 289.5 GANC ENSG00000214013 Glucosidase, alpha; neutral C 15 42273233-42356935 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA016949 Approved Approved Nucleoplasm
Actin filaments Lung cancer:9.76e-4 (favourable) Expressed in all Expressed in all lung: 42.6 GART PGFT, PRGS ENSG00000159131 Phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase 21 33503931-33543491 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA002119, HPA005779 Approved Uncertain Nucleoplasm
Mitochondria
Cytosol Renal cancer:3.95e-6 (unfavourable), Head and neck cancer:5.05e-5 (unfavourable), Liver cancer:9.82e-5 (unfavourable), Pancreatic cancer:2.19e-4 (unfavourable) Expressed in all Expressed in all testis: 55.3 GCGR GGR ENSG00000215644 Glucagon receptor 17 81804132-81814013 FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA071228 Approved Golgi apparatus Tissue enhanced Group enriched 7 adrenal gland: 6.6;kidney: 8.5;liver: 20.9;parathyroid gland: 9.4 skin: 1.6 GGCX VKCFD1 ENSG00000115486 Gamma-glutamyl carboxylase 2 85544723-85561547 Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA018284 Approved Endometrial cancer:1.82e-6 (unfavourable) Expressed in all Expressed in all liver: 61.2 GGPS1 GGPPS1 ENSG00000152904 Geranylgeranyl diphosphate synthase 1 1 235327350-235344532 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA029472 Supported Liver cancer:6.69e-4 (unfavourable) Expressed in all Expressed in all testis: 89.7 GHR GHBP ENSG00000112964 Growth hormone receptor 5 42423777-42721878 Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA045339, HPA057705 Supported Supported Plasma membrane
Cytosol
Cytoplasmic bodies Liver cancer:2.73e-6 (favourable) Mixed Group enriched 5 adipose tissue: 91.1;liver: 110.5 prostate: 18.4 GHRHR ENSG00000106128 Growth hormone releasing hormone receptor 7 30938669-30993254 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level Tissue enhanced Not detected adrenal gland: 0.5 GLP1R ENSG00000112164 Glucagon-like peptide 1 receptor 6 39048798-39087743 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level Mixed Tissue enhanced cerebral cortex: 1.9;heart muscle: 1.8 pancreas: 1.5 GLP2R ENSG00000065325 Glucagon-like peptide 2 receptor 17 9822206-9892102 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level CAB022690, HPA049244 Supported Supported Plasma membrane Tissue enhanced Tissue enhanced gallbladder: 19.4 duodenum: 10.4 GLRA1 STHE ENSG00000145888 Glycine receptor, alpha 1 5 151822513-151924842 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA016502 Uncertain Not detected Not detected adrenal gland: 0.4 GLRA2 GLR ENSG00000101958 Glycine receptor, alpha 2 X 14529298-14731812 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB070422 Approved Mixed Group enriched 10 cerebral cortex: 6.2;colon: 1.4;rectum: 4.3 testis: 0.3 GLRA3 ENSG00000145451 Glycine receptor, alpha 3 4 174636914-174829314 FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level Tissue enhanced Group enriched 6 breast: 2.6;cerebral cortex: 9.1 adrenal gland: 1.0 GLRB ENSG00000109738 Glycine receptor, beta 4 157076057-157172090 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA052363 Approved Renal cancer:4.89e-4 (favourable) Mixed Tissue enhanced cerebral cortex: 62.2;parathyroid gland: 62.0 cervix, uterine: 14.0 GNRHR GRHR, LHRHR ENSG00000109163 Gonadotropin-releasing hormone receptor 4 67739328-67754360 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level HPA013424 Supported Not detected Tissue enhanced parathyroid gland: 1.2 adrenal gland: 1.0 GRIA1 GluA1, GLUR1, GLURA ENSG00000155511 Glutamate receptor, ionotropic, AMPA 1 5 153489615-153813869 FDA approved drug targets, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB001965, HPA035202 Supported Tissue enriched Tissue enriched 6 cerebral cortex: 67.3 lung: 10.6 GRIK1 GluK1, GLUR5 ENSG00000171189 Glutamate receptor, ionotropic, kainate 1 21 29536933-29940033 FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA014623 Uncertain Glioma:9.12e-4 (unfavourable) Group enriched Tissue enhanced adrenal gland: 16.8;cerebral cortex: 9.1 prostate: 3.9 GRIN1 GluN1, NMDAR1 ENSG00000176884 Glutamate receptor, ionotropic, N-methyl D-aspartate 1 9 137138390-137168762 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters Evidence at protein level CAB006831 Approved Mixed Tissue enriched 202 cerebral cortex: 152.3 prostate: 0.7 GRIN2A GluN2A, NMDAR2A ENSG00000183454 Glutamate receptor, ionotropic, N-methyl D-aspartate 2A 16 9753404-10182754 Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins Evidence at protein level CAB022725 Supported Mixed Tissue enriched 5 cerebral cortex: 25.0 testis: 4.7 GRIN2B GluN2B, NMDAR2B ENSG00000273079 Glutamate receptor, ionotropic, N-methyl D-aspartate 2B 12 13537337-13981957 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level HPA069762 Approved Not detected Tissue enriched 25 cerebral cortex: 13.2 adipose tissue: 0.5 GRIN2C GluN2C, NMDAR2C ENSG00000161509 Glutamate receptor, ionotropic, N-methyl D-aspartate 2C 17 74842023-74861504 FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level Tissue enhanced Tissue enhanced cerebral cortex: 9.6;heart muscle: 7.8;thyroid gland: 14.0 salivary gland: 4.4 GRIN2D EB11, GluN2D, NMDAR2D, NR2D ENSG00000105464 Glutamate receptor, ionotropic, N-methyl D-aspartate 2D 19 48394875-48444931 FDA approved drug targets, Predicted membrane proteins Evidence at protein level Mixed Tissue enhanced cerebral cortex: 2.3 placenta: 1.3 GRIN3A GluN3A ENSG00000198785 Glutamate receptor, ionotropic, N-methyl-D-aspartate 3A 9 101569353-101738580 FDA approved drug targets, Predicted membrane proteins Evidence at protein level Tissue enriched Group enriched 5 cerebral cortex: 12.4;cervix, uterine: 2.5 seminal vesicle: 1.4 GRIN3B GluN3B ENSG00000116032 Glutamate receptor, ionotropic, N-methyl-D-aspartate 3B 19 1000419-1009732 FDA approved drug targets, Predicted membrane proteins Evidence at transcript level Mixed Tissue enhanced fallopian tube: 2.1;spleen: 1.2 lung: 0.7 GRM5 GPRC1E, mGlu5, MGLUR5, PPP1R86 ENSG00000168959 Glutamate receptor, metabotropic 5 11 88504576-89065945 FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Not detected Tissue enriched 9 cerebral cortex: 27.3 testis: 3.1 GSR ENSG00000104687 Glutathione reductase 8 30678061-30727926 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA001538, CAB008632 Approved Supported Plasma membrane
Cytosol Liver cancer:3.26e-5 (unfavourable), Colorectal cancer:4.08e-5 (favourable), Renal cancer:1.80e-4 (favourable), Cervical cancer:3.37e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 77.8 GSS ENSG00000100983 Glutathione synthetase 20 34928430-34955817 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA054508, HPA059315 Supported Supported Nucleus Renal cancer:7.31e-6 (favourable), Liver cancer:7.21e-5 (unfavourable) Expressed in all Expressed in all epididymis: 104.1 GUCY1A2 GC-SA2, GUC1A2 ENSG00000152402 Guanylate cyclase 1, soluble, alpha 2 11 106674012-107018524 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level CAB009534 Uncertain Renal cancer:3.02e-5 (unfavourable) Mixed Tissue enhanced placenta: 25.4 endometrium: 21.0 GUCY2C GUC2C, STAR ENSG00000070019 Guanylate cyclase 2C 12 14612632-14696585 Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA037655, HPA073759 Uncertain Uncertain Vesicles Liver cancer:1.37e-5 (unfavourable) Group enriched Group enriched 13 colon: 38.4;duodenum: 70.6;rectum: 48.1;small intestine: 74.7 appendix: 4.5 HBA1 HBA-T3 ENSG00000206172 Hemoglobin, alpha 1 16 176680-177522 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB032534, HPA043780 Supported Tissue enhanced Tissue enriched 5 bone marrow: 17168.0 placenta: 3411.4 HBA2 HBA-T2 ENSG00000188536 Hemoglobin, alpha 2 16 172847-173710 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB038417, HPA043780 Supported Expressed in all Group enriched 26 bone marrow: 18412.0;placenta: 4269.5 spleen: 435.5 HBB beta-globin, CD113t-C, HBD ENSG00000244734 Hemoglobin, beta 11 5225464-5229395 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB009526, HPA043234 Supported Expressed in all Tissue enriched 9 bone marrow: 78261.0 placenta: 8978.3 HCAR2 GPR109A, HCA2, HM74A, NIACR1, Puma-g, PUMAG ENSG00000182782 Hydroxycarboxylic acid receptor 2 12 122701293-122703343 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA028660 Approved Approved Cell Junctions Group enriched Tissue enhanced spleen: 36.5 esophagus: 25.6 HCAR3 GPR109B, HCA3, HM74 ENSG00000255398 Hydroxycarboxylic acid receptor 3 12 122714756-122716892 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA028660 Approved Approved Cell Junctions Mixed Tissue enhanced bone marrow: 16.7;spleen: 22.1 appendix: 12.6 HCRTR1 OX1R ENSG00000121764 Hypocretin (orexin) receptor 1 1 31617686-31632518 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA014018 Approved Not detected Mixed adrenal gland: 1.2 HCRTR2 OX2R ENSG00000137252 Hypocretin (orexin) receptor 2 6 55106460-55282620 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA054516 Supported Not detected Not detected kidney: 0.6 HDAC1 GON-10, HD1, RPD3L1 ENSG00000116478 Histone deacetylase 1 1 32292086-32333635 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB005017, HPA029693, CAB068191 Supported Validated Nucleoplasm Liver cancer:5.76e-7 (unfavourable), Renal cancer:1.04e-5 (unfavourable) Expressed in all Expressed in all lymph node: 140.7 HDAC2 RPD3, YAF1 ENSG00000196591 Histone deacetylase 2 6 113933028-114011308 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB005054, HPA011727 Supported Validated Nucleus Liver cancer:5.39e-10 (unfavourable), Breast cancer:7.07e-4 (unfavourable) Expressed in all Expressed in all testis: 142.0 HDAC3 HD3, RPD3, RPD3-2 ENSG00000171720 Histone deacetylase 3 5 141620876-141636870 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level CAB005583, HPA052052 Supported Supported Nucleoplasm
Golgi apparatus Renal cancer:2.65e-6 (unfavourable), Colorectal cancer:3.39e-4 (favourable), Pancreatic cancer:3.95e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 51.1 HDAC6 FLJ16239, HD6, JM21, KIAA0901, PPP1R90 ENSG00000094631 Histone deacetylase 6 X 48801377-48824982 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA003714, CAB004236, HPA026321 Approved Supported Nucleoplasm Urothelial cancer:3.34e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 50.4 HDAC9 HD7, HDAC, HDAC7B, KIAA0744, MITR ENSG00000048052 Histone deacetylase 9 7 18086949-19002416 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA028926 Uncertain Approved Nucleoplasm Mixed Mixed spleen: 25.0 HMGCR ENSG00000113161 3-hydroxy-3-methylglutaryl-CoA reductase 5 75336329-75362104 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA008338, CAB016797 Approved Renal cancer:9.42e-6 (favourable) Expressed in all Expressed in all cerebral cortex: 87.8 HMMR CD168, RHAMM ENSG00000072571 Hyaluronan-mediated motility receptor (RHAMM) 5 163460203-163491945 CD markers, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level CAB002433, HPA040025, HPA043926, HPA061524 Approved Validated Microtubules
Centrosome
Cytosol Liver cancer:1.93e-7 (unfavourable), Pancreatic cancer:3.71e-5 (unfavourable), Lung cancer:1.09e-4 (unfavourable), Head and neck cancer:5.52e-4 (unfavourable) Mixed Tissue enhanced testis: 50.3 lymph node: 21.9 HPD 4-HPPD, 4HPPD, GLOD3, PPD ENSG00000158104 4-hydroxyphenylpyruvate dioxygenase 12 121839527-121863596 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA038321, HPA038322 Supported Uncertain Nuclear speckles Tissue enriched Group enriched 85 kidney: 526.3;liver: 1290.5 testis: 10.6 HPRT1 HGPRT, HPRT ENSG00000165704 Hypoxanthine phosphoribosyltransferase 1 X 134460153-134520513 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA006360, CAB012200 Supported Supported Cytosol Head and neck cancer:1.35e-5 (unfavourable) Expressed in all Expressed in all testis: 138.3 HRH1 ENSG00000196639 Histamine receptor H1 3 11137093-11263557 FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA029740 Uncertain Supported Plasma membrane
Cytosol Pancreatic cancer:1.27e-5 (unfavourable) Mixed Mixed cerebral cortex: 12.4 HRH2 ENSG00000113749 Histamine receptor H2 5 175658030-175686242 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA013770 Approved Tissue enhanced Tissue enhanced bone marrow: 26.4 placenta: 17.9 HRH3 GPCR97 ENSG00000101180 Histamine receptor H3 20 62214970-62220267 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level Mixed Tissue enriched 17 cerebral cortex: 11.1 adrenal gland: 0.6 HSD3B1 HSD3B, HSDB3, SDR11E1 ENSG00000203857 Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 1 119507198-119515054 Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA043261, HPA043264, HPA044028 Supported Urothelial cancer:4.59e-5 (favourable) Tissue enhanced Tissue enriched 12 placenta: 110.1 small intestine: 8.9 HSD3B2 SDR11E2 ENSG00000203859 Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 1 119414931-119423035 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA043261, HPA043264, HPA044028 Supported Tissue enhanced Tissue enriched 436 adrenal gland: 2394.6 testis: 5.4 HTR1A 5-HT1A, ADRB2RL1, ADRBRL1 ENSG00000178394 5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled 5 63960356-63962507 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA018073 Uncertain Not detected Group enriched 10 cerebral cortex: 1.9;ovary: 3.9 testis: 0.2 HTR1B 5-HT1B, 5-HT1DB, HTR1D2, S12 ENSG00000135312 5-hydroxytryptamine (serotonin) receptor 1B, G protein-coupled 6 77462205-77463464 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level HPA028808 Approved Uncertain Plasma membrane Mixed Tissue enhanced placenta: 13.7;stomach: 5.8 cerebral cortex: 2.8 HTR1D 5-HT1D, HT1DA, HTRL, RDC4 ENSG00000179546 5-hydroxytryptamine (serotonin) receptor 1D, G protein-coupled 1 23191895-23194729 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level Liver cancer:1.86e-4 (unfavourable), Pancreatic cancer:5.30e-4 (unfavourable) Mixed Group enriched 8 duodenum: 9.7;gallbladder: 2.5;small intestine: 9.3 fallopian tube: 0.8 HTR1F 5-HT1F, HTR1EL ENSG00000179097 5-hydroxytryptamine (serotonin) receptor 1F, G protein-coupled 3 87990696-87993835 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA005555 Uncertain Not detected Tissue enhanced placenta: 2.7 cerebral cortex: 1.0 HTR2A 5-HT2A, HTR2 ENSG00000102468 5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled 13 46831550-46897076 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA014011 Supported Not detected Tissue enriched 8 cerebral cortex: 32.3 smooth muscle: 3.8 HTR2B 5-HT(2B), 5-HT2B ENSG00000135914 5-hydroxytryptamine (serotonin) receptor 2B, G protein-coupled 2 231108230-231125118 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level CAB011448, HPA012867, HPA063658 Approved Approved Nucleoplasm Mixed Tissue enhanced cervix, uterine: 31.1;endometrium: 30.0;smooth muscle: 23.0 adrenal gland: 19.1 HTR2C 5-HT2C, 5HTR2C, HTR1C ENSG00000147246 5-hydroxytryptamine (serotonin) receptor 2C, G protein-coupled X 114584078-114910061 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level Tissue enhanced Tissue enriched 5 cerebral cortex: 3.1 cervix, uterine: 0.5 HTR3A 5-HT3A, 5-HT3R, HTR3 ENSG00000166736 5-hydroxytryptamine (serotonin) receptor 3A, ionotropic 11 113974881-113990313 FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level Endometrial cancer:1.26e-4 (unfavourable), Cervical cancer:6.26e-4 (favourable) Tissue enriched Group enriched 5 appendix: 2.9;lymph node: 7.9;tonsil: 7.4 small intestine: 1.1 HTR4 5-HT4 ENSG00000164270 5-hydroxytryptamine (serotonin) receptor 4, G protein-coupled 5 148451032-148677235 FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA040591 Approved Not detected Tissue enhanced duodenum: 5.0;small intestine: 10.2 heart muscle: 3.5 HTR6 5-HT6, 5-HT6R ENSG00000158748 5-hydroxytryptamine (serotonin) receptor 6, G protein-coupled 1 19665287-19679562 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level Tissue enhanced Not detected cerebral cortex: 0.8 HTR7 5-HT7 ENSG00000148680 5-hydroxytryptamine (serotonin) receptor 7, adenylate cyclase-coupled 10 90740823-90857698 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, RAS pathway related proteins Evidence at protein level CAB022708 Uncertain Supported Nuclear speckles
Plasma membrane
Cytosol Group enriched Group enriched 8 parathyroid gland: 43.9;testis: 16.0 urinary bladder: 3.9 ICAM1 BB2, CD54 ENSG00000090339 Intercellular adhesion molecule 1 19 10270835-10286615 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA002126, CAB002142, HPA004877 Supported Uncertain Plasma membrane
Cytosol Renal cancer:1.32e-6 (unfavourable), Breast cancer:7.09e-4 (favourable) Expressed in all Expressed in all lung: 256.0 IDE ENSG00000119912 Insulin-degrading enzyme 10 92451684-92574076 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA063478 Approved Endometrial cancer:3.53e-4 (favourable), Colorectal cancer:3.69e-4 (favourable) Expressed in all Expressed in all skin: 63.5 IFNAR1 IFNAR, IFRC ENSG00000142166 Interferon (alpha, beta and omega) receptor 1 21 33324477-33359862 Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA018015, HPA029226 Approved Approved Cytosol Expressed in all Expressed in all parathyroid gland: 60.2 IFNAR2 IFNABR ENSG00000159110 Interferon (alpha, beta and omega) receptor 2 21 33229901-33265675 Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB025889 Approved Renal cancer:7.54e-7 (unfavourable) Expressed in all Expressed in all spleen: 59.7 IFNG ENSG00000111537 Interferon, gamma 12 68154768-68159747 Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB010344 Approved Mixed Tissue enhanced appendix: 4.9;bone marrow: 7.6;lymph node: 8.0 lung: 2.5 IFNGR1 CD119, IFNGR ENSG00000027697 Interferon gamma receptor 1 6 137197484-137219449 CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA029213, HPA063871 Approved Supported Endoplasmic reticulum
Vesicles
Plasma membrane Renal cancer:5.48e-4 (unfavourable) Expressed in all Expressed in all spleen: 225.2 IFNGR2 AF-1, IFNGT1 ENSG00000159128 Interferon gamma receptor 2 (interferon gamma transducer 1) 21 33402896-33479348 Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA001535 Approved Approved Nucleoplasm
Golgi apparatus Renal cancer:1.13e-10 (unfavourable), Liver cancer:3.25e-4 (unfavourable) Expressed in all Mixed spleen: 10.3 IGF1R CD221, IGFIR, IGFR, JTK13, MGC18216 ENSG00000140443 Insulin-like growth factor 1 receptor 15 98648971-98964530 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins Evidence at protein level CAB010268, HPA045563 Uncertain Uncertain Vesicles Renal cancer:3.75e-7 (favourable) Expressed in all Mixed prostate: 24.7 IKBKB IKK-beta, IKK2, IKKB, NFKBIKB ENSG00000104365 Inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta 8 42271302-42332653 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level HPA001249, CAB004447 Approved Approved Cytosol Urothelial cancer:1.46e-6 (favourable) Expressed in all Mixed parathyroid gland: 18.8 IL11RA ENSG00000137070 Interleukin 11 receptor, alpha 9 34650702-34661892 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA013162, CAB032830, HPA036652 Supported Renal cancer:6.56e-4 (unfavourable) Expressed in all Expressed in all skin: 72.6 IL17A CTLA8, IL-17, IL-17A, IL17 ENSG00000112115 Interleukin 17A 6 52186387-52190638 Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA052258 Uncertain Not detected Tissue enhanced appendix: 1.0;tonsil: 1.4;urinary bladder: 1.6 gallbladder: 0.3 IL1B IL-1B, IL1-BETA, IL1F2 ENSG00000125538 Interleukin 1, beta 2 112829751-112836903 Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level Renal cancer:7.49e-5 (unfavourable), Cervical cancer:1.31e-4 (unfavourable) Mixed Tissue enhanced appendix: 69.5;bone marrow: 106.7 adipose tissue: 52.7 IL1R1 CD121A, D2S1473, IL1R, IL1RA ENSG00000115594 Interleukin 1 receptor, type I 2 102064544-102179874 Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA001237, HPA005823, CAB007779, HPA029560 Approved Validated Vesicles Renal cancer:6.92e-6 (unfavourable) Expressed in all Expressed in all cervix, uterine: 244.6 IL2RA CD25, IDDM10, IL2R ENSG00000134460 Interleukin 2 receptor, alpha 10 6010689-6062325 Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002419, HPA054622 Supported Renal cancer:2.08e-9 (unfavourable) Mixed Tissue enhanced adipose tissue: 23.9;appendix: 20.4;lymph node: 20.7 tonsil: 12.5 IL2RB CD122, IL15RB ENSG00000100385 Interleukin 2 receptor, beta 22 37125838-37175054 Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA062657 Supported Renal cancer:3.50e-7 (unfavourable), Endometrial cancer:3.18e-5 (favourable), Colorectal cancer:6.76e-4 (favourable) Expressed in all Tissue enhanced spleen: 68.3 placenta: 52.4 IL2RG CD132, CIDX, IMD4, SCIDX1 ENSG00000147168 Interleukin 2 receptor, gamma X 71107404-71112108 Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA046641, HPA049691 Supported Approved Vesicles Renal cancer:2.28e-7 (unfavourable), Endometrial cancer:1.73e-4 (favourable) Expressed in all Tissue enhanced lymph node: 277.4;tonsil: 290.2 appendix: 188.7 IL3RA CD123 ENSG00000185291 Interleukin 3 receptor, alpha (low affinity) X 1336616-1382689 CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA003539, CAB018374 Approved Cervical cancer:4.27e-4 (favourable), Breast cancer:9.78e-4 (favourable) Expressed in all Expressed in all lung: 33.8 IL5 EDF, IL-5, TRF ENSG00000113525 Interleukin 5 5 132541444-132556838 Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB010304 Approved Not detected Tissue enriched 9 testis: 9.7 epididymis: 1.1 IL6 BSF2, HGF, HSF, IFNB2, IL-6 ENSG00000136244 Interleukin 6 7 22725884-22732002 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB023406, CAB072821 Supported Approved Vesicles Renal cancer:1.10e-11 (unfavourable) Mixed Tissue enhanced adipose tissue: 135.4 urinary bladder: 76.8 IL6R CD126 ENSG00000160712 Interleukin 6 receptor 1 154405193-154469450 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Pancreatic cancer:1.65e-4 (favourable) Expressed in all Expressed in all appendix: 34.4 IMPDH1 LCA11, RP10, sWSS2608 ENSG00000106348 IMP (inosine 5'-monophosphate) dehydrogenase 1 7 128392277-128410252 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA001400 Approved Supported Cytosol
Rods & Rings Renal cancer:1.78e-12 (unfavourable), Liver cancer:1.12e-7 (unfavourable), Urothelial cancer:3.72e-5 (unfavourable), Glioma:1.17e-4 (unfavourable), Cervical cancer:3.87e-4 (unfavourable) Expressed in all Expressed in all appendix: 47.2 IMPDH2 ENSG00000178035 IMP (inosine 5'-monophosphate) dehydrogenase 2 3 49024325-49029408 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA001400, CAB020717 Approved Validated Cytosol
Rods & Rings Liver cancer:3.22e-4 (unfavourable) Expressed in all Expressed in all ovary: 421.1 INSR CD220 ENSG00000171105 Insulin receptor 19 7112255-7294034 CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins Evidence at protein level HPA036302, HPA036303 Uncertain Supported Vesicles Expressed in all Expressed in all ovary,spleen: 35.4 ITGA2B CD41, CD41B, GP2B, PPP1R93 ENSG00000005961 Integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41) 17 44372180-44389505 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB018611, HPA031168, HPA031169, HPA031170, HPA031171 Supported Uncertain Nucleoplasm
Cell Junctions
Cytosol Mixed Tissue enhanced bone marrow: 11.2;epididymis: 28.6 testis: 4.4 ITGA4 CD49D ENSG00000115232 Integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor) 2 181457202-181536187 Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA064041 Approved Golgi apparatus
Vesicles Renal cancer:3.08e-5 (unfavourable), Head and neck cancer:8.29e-4 (favourable) Mixed Tissue enhanced spleen: 68.6 appendix: 51.2 ITGAL CD11A, LFA-1 ENSG00000005844 Integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide) 16 30472658-30523185 CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB025011 Supported Renal cancer:2.69e-5 (unfavourable), Endometrial cancer:5.63e-5 (favourable), Head and neck cancer:3.34e-4 (favourable), Melanoma:5.57e-4 (favourable) Expressed in all Tissue enhanced lymph node: 80.1;spleen: 82.2 appendix: 54.3 ITGAV CD51, MSK8, VNRA, VTNR ENSG00000138448 Integrin, alpha V 2 186590065-186680901 Cancer-related genes, CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002499, HPA004856 Supported Approved Focal adhesion sites
Cytosol Stomach cancer:1.05e-6 (unfavourable), Liver cancer:2.08e-4 (unfavourable), Pancreatic cancer:5.07e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 187.7 ITGB1 CD29, FNRB, GPIIA, MDF2, MSK12 ENSG00000150093 Integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) 10 32900319-33005792 Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level CAB003434 Approved Supported Endoplasmic reticulum
Plasma membrane
Focal adhesion sites Lung cancer:3.36e-6 (unfavourable), Cervical cancer:5.01e-4 (unfavourable) Expressed in all Expressed in all smooth muscle: 1058.2 ITGB3 CD61, GP3A, GPIIIa ENSG00000259207 Integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) 17 47253846-47311816 Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA027852 Supported Group enriched Tissue enhanced thyroid gland: 95.1 smooth muscle: 36.3 ITGB7 ENSG00000139626 Integrin, beta 7 12 53191318-53207307 Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA042277 Approved Plasma membrane
Cytosol Mixed Mixed spleen: 32.8 JAK1 JAK1A, JAK1B, JTK3 ENSG00000162434 Janus kinase 1 1 64833229-64966504 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB013088 Approved Renal cancer:2.67e-4 (favourable), Colorectal cancer:2.81e-4 (favourable), Breast cancer:9.63e-4 (favourable) Expressed in all Expressed in all lymph node: 117.1 JAK2 JTK10 ENSG00000096968 Janus kinase 2 9 4985033-5128183 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB013089, HPA040820, HPA043870 Approved Supported Nucleoplasm
Plasma membrane
Focal adhesion sites Expressed in all Mixed appendix: 25.4 JAK3 JAK-3, JAK3_HUMAN, JAKL, L-JAK, LJAK ENSG00000105639 Janus kinase 3 19 17824780-17848071 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA070314 Supported Approved Cytosol Renal cancer:2.89e-14 (unfavourable), Cervical cancer:6.42e-5 (favourable) Expressed in all Tissue enhanced appendix: 49.9;lymph node: 47.2 tonsil: 28.2 JUN AP-1, c-Jun ENSG00000177606 Jun proto-oncogene 1 58780788-58784327 Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB003801, CAB007780, HPA059474 Supported Validated Nucleoplasm Expressed in all Expressed in all thyroid gland: 312.9 KCNA1 AEMK, HUK1, Kv1.1, MBK1, RBK1 ENSG00000111262 Potassium channel, voltage gated shaker related subfamily A, member 1 12 4909905-4931361 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level CAB022365 Uncertain Not detected Tissue enriched 6 cerebral cortex: 13.5 parathyroid gland: 2.0 KCNA10 Kv1.8 ENSG00000143105 Potassium channel, voltage gated shaker related subfamily A, member 10 1 110517251-110518838 FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA015061, CAB022564 Uncertain Uncertain Nucleoplasm
Cytosol Not detected Tissue enhanced testis: 1.0 spleen: 0.2 KCNA2 HK4, Kv1.2 ENSG00000177301 Potassium channel, voltage gated shaker related subfamily A, member 2 1 110593580-110631474 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level CAB001976 Supported Tissue enhanced Tissue enriched 5 cerebral cortex: 20.7 thyroid gland: 3.8 KCNA3 HLK3, HPCN3, Kv1.3, MK3 ENSG00000177272 Potassium channel, voltage gated shaker related subfamily A, member 3 1 110672465-110675033 FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA016625 Approved Mixed Mixed lymph node: 10.7 KCNA4 HK1, HPCN2, KCNA4L, Kv1.4 ENSG00000182255 Potassium channel, voltage gated shaker related subfamily A, member 4 11 30009741-30017023 FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level CAB001977, HPA016422 Approved Not detected Tissue enhanced adrenal gland: 7.9;cerebral cortex: 4.3 heart muscle: 1.2 KCNA5 HK2, HPCN1, Kv1.5 ENSG00000130037 Potassium channel, voltage gated shaker related subfamily A, member 5 12 5043989-5046788 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA021516, CAB022562 Approved Mixed Tissue enhanced heart muscle: 20.8 esophagus: 5.6 KCNA6 ENSG00000151079 Potassium voltage-gated channel subfamily A member 6 12 4809176-4813412 FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels Evidence at transcript level CAB011539, HPA014418 Approved Not detected Not detected appendix,duodenum,lymph node: 0.1 KCNA7 HAK6, Kv1.7 ENSG00000104848 Potassium channel, voltage gated shaker related subfamily A, member 7 19 49067418-49072941 FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels Evidence at transcript level Not detected Tissue enriched 37 skeletal muscle: 26.2 esophagus: 0.7 KCNB1 Kv2.1 ENSG00000158445 Potassium channel, voltage gated Shab related subfamily B, member 1 20 49363877-49484297 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level CAB001979, HPA042434 Supported Mixed Tissue enhanced adipose tissue: 11.0;cerebral cortex: 21.0 fallopian tube: 7.5 KCNB2 Kv2.2 ENSG00000182674 Potassium channel, voltage gated Shab related subfamily B, member 2 8 72537391-72938349 FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA065970 Approved Nucleoli
Plasma membrane
Midbody Not detected Tissue enhanced cerebral cortex: 3.2;spleen: 3.4 fallopian tube,testis: 0.7 KCNC1 Kv3.1 ENSG00000129159 Potassium channel, voltage gated Shaw related subfamily C, member 1 11 17734812-17783055 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA047634, HPA048249 Supported Approved Nucleus
Nuclear membrane
Vesicles
Cytosol Tissue enhanced Tissue enriched 8 cerebral cortex: 16.5 testis: 1.9 KCNC2 Kv3.2 ENSG00000166006 Potassium channel, voltage gated Shaw related subfamily C, member 2 12 75040077-75209868 FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA019664, CAB022571 Uncertain Supported Plasma membrane
Cytosol Group enriched Tissue enriched 11 cerebral cortex: 46.5 prostate: 4.2 KCNC3 Kv3.3, SCA13 ENSG00000131398 Potassium channel, voltage gated Shaw related subfamily C, member 3 19 50311937-50333515 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA018041 Uncertain Renal cancer:1.23e-4 (unfavourable) Mixed Tissue enhanced parathyroid gland: 39.3 cerebral cortex: 19.9 KCND1 Kv4.1 ENSG00000102057 Potassium channel, voltage gated Shal related subfamily D, member 1 X 48961378-48971569 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA000524, HPA001066 Approved Approved Nucleus Pancreatic cancer:2.66e-6 (favourable) Mixed Mixed gallbladder: 4.0 KCND2 KIAA1044, Kv4.2, RK5 ENSG00000184408 Potassium channel, voltage gated Shal related subfamily D, member 2 7 120273668-120750331 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA029068 Approved Tissue enhanced Tissue enhanced cerebral cortex: 20.8 gallbladder: 6.9 KCND3 KSHIVB, Kv4.3, SCA19, SCA22 ENSG00000171385 Potassium channel, voltage gated Shal related subfamily D, member 3 1 111770662-111989155 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA029452 Approved Mixed Mixed cerebral cortex: 26.8 KCNE1 ISK, JLNS2, LQT5, minK ENSG00000180509 Potassium channel, voltage gated subfamily E regulatory beta subunit 1 21 34446688-34512275 Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level Not detected Tissue enhanced fallopian tube: 16.4 heart muscle: 3.7 KCNH2 erg1, HERG, Kv11.1, LQT2 ENSG00000055118 Potassium channel, voltage gated eag related subfamily H, member 2 7 150944961-150978315 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level Endometrial cancer:6.06e-5 (unfavourable), Pancreatic cancer:5.61e-4 (favourable) Mixed Tissue enhanced bone marrow: 24.1;testis: 27.4 parathyroid gland: 12.9 KCNJ1 Kir1.1, ROMK1 ENSG00000151704 Potassium channel, inwardly rectifying subfamily J, member 1 11 128836315-128867373 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA026962 Supported Tissue enriched Tissue enriched 118 kidney: 209.0 epididymis: 1.7 KCNJ11 BIR, Kir6.2 ENSG00000187486 Potassium channel, inwardly rectifying subfamily J, member 11 11 17385859-17389331 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA048891 Approved Renal cancer:1.56e-4 (favourable) Mixed Tissue enhanced skeletal muscle: 32.7 cerebral cortex: 10.2 KCNJ12 hIRK1, IRK2, KCNJN1, Kir2.2, Kir2.2v ENSG00000184185 Potassium channel, inwardly rectifying subfamily J, member 12 17 21376197-21419872 FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA027021 Approved Uncertain Nucleoplasm
Golgi apparatus
Cytosol Endometrial cancer:7.84e-5 (unfavourable) Mixed Group enriched 5 parathyroid gland: 18.9;skeletal muscle: 23.1 heart muscle: 3.9 KCNJ8 Kir6.1 ENSG00000121361 Potassium channel, inwardly rectifying subfamily J, member 8 12 21764955-21775581 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA031066 Uncertain Renal cancer:1.62e-6 (unfavourable), Colorectal cancer:9.29e-4 (unfavourable) Expressed in all Mixed seminal vesicle: 31.6 KCNK2 K2p2.1, TREK-1 ENSG00000082482 Potassium channel, two pore domain subfamily K, member 2 1 215005775-215237093 FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA056054 Uncertain Approved Mitochondria
Cytosol Mixed Tissue enhanced adrenal gland: 75.5 thyroid gland: 17.3 KCNK3 K2p3.1, TASK, TASK-1 ENSG00000171303 Potassium channel, two pore domain subfamily K, member 3 2 26692690-26733420 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level Renal cancer:2.37e-7 (unfavourable) Tissue enhanced Tissue enhanced adrenal gland: 112.3;placenta: 35.5 lung: 19.9 KCNK9 K2p9.1, TASK-3, TASK3 ENSG00000169427 Potassium channel, two pore domain subfamily K, member 9 8 139600838-139703056 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level Mixed Group enriched 7 adrenal gland: 4.8;cerebral cortex: 4.8 cervix, uterine: 0.7 KCNMA1 KCa1.1, mSLO1, SLO ENSG00000156113 Potassium channel, calcium activated large conductance subfamily M alpha, member 1 10 76869601-77638595 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA054648 Approved Mixed Tissue enhanced smooth muscle: 147.6 endometrium: 122.5 KCNN4 hIKCa1, hKCa4, hSK4, IK, KCa3.1 ENSG00000104783 Potassium channel, calcium activated intermediate/small conductance subfamily N alpha, member 4 19 43766533-43781257 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA053841, HPA059622 Approved Renal cancer:1.05e-14 (unfavourable), Urothelial cancer:1.75e-4 (favourable), Glioma:3.77e-4 (unfavourable), Pancreatic cancer:4.56e-4 (unfavourable) Expressed in all Tissue enhanced salivary gland: 74.3 stomach: 37.1 KCNQ1 JLNS1, KCNA8, KCNA9, Kv7.1, KVLQT1, LQT, LQT1 ENSG00000053918 Potassium channel, voltage gated KQT-like subfamily Q, member 1 11 2444684-2849109 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level CAB018656, HPA048553 Supported Stomach cancer:9.85e-4 (favourable) Expressed in all Tissue enhanced adrenal gland: 134.2;thyroid gland: 102.8 seminal vesicle: 60.3 KCNQ2 BFNC, EBN, EBN1, ENB1, HNSPC, KCNA11, Kv7.2 ENSG00000075043 Potassium channel, voltage gated KQT-like subfamily Q, member 2 20 63400210-63472677 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA016642, HPA057112 Approved Approved Endoplasmic reticulum Tissue enriched Tissue enriched 7 cerebral cortex: 56.3 adrenal gland: 8.2 KCNQ3 EBN2, Kv7.3 ENSG00000184156 Potassium channel, voltage gated KQT-like subfamily Q, member 3 8 132120859-132480953 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level Mixed Tissue enriched 14 cerebral cortex: 26.9 adrenal gland: 1.9 KDR CD309, FLK1, VEGFR, VEGFR2 ENSG00000128052 Kinase insert domain receptor 4 55078477-55125589 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins Evidence at protein level CAB004028 Approved Supported Plasma membrane Renal cancer:7.26e-4 (unfavourable) Expressed in all Tissue enhanced placenta: 118.2 thyroid gland: 54.5 KEAP1 INrf2, KIAA0132, KLHL19, MGC10630, MGC1114, MGC20887, MGC4407, MGC9454 ENSG00000079999 Kelch-like ECH-associated protein 1 19 10486120-10503741 Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA005558, CAB025337 Approved Supported Nucleoplasm
Microtubule organizing center
Cytosol Cervical cancer:3.28e-4 (favourable) Expressed in all Expressed in all skeletal muscle: 49.4 KIT C-Kit, CD117, PBT, SCFR ENSG00000157404 V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog 4 54657918-54740715 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins Evidence at protein level CAB003288, HPA004471, CAB068253, CAB072867, HPA073252 Supported Supported Plasma membrane Renal cancer:5.63e-4 (favourable) Mixed Tissue enhanced breast: 133.8 thyroid gland: 78.4 KLKB1 KLK3 ENSG00000164344 Kallikrein B, plasma (Fletcher factor) 1 4 186208979-186258471 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level Tissue enriched Tissue enriched 45 liver: 154.2 gallbladder,kidney: 3.4 LCK ENSG00000182866 LCK proto-oncogene, Src family tyrosine kinase 1 32251239-32286165 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA003494, CAB003816 Supported Approved Golgi apparatus Endometrial cancer:2.96e-6 (favourable), Renal cancer:2.60e-5 (unfavourable), Melanoma:5.65e-5 (favourable), Head and neck cancer:2.91e-4 (favourable) Mixed Tissue enhanced appendix: 68.8;lymph node: 127.7;tonsil: 75.1 spleen: 55.2 LEPR CD295, OBR ENSG00000116678 Leptin receptor 1 65420652-65641559 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA030899 Approved Vesicles Tissue enriched Mixed liver: 69.9 LHCGR HHG, LCGR, LGR2, LHR, ULG5 ENSG00000138039 Luteinizing hormone/choriogonadotropin receptor 2 48686775-48755730 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB009814 Uncertain Not detected Group enriched 5 adipose tissue: 1.3;adrenal gland: 1.1;ovary: 1.5;testis: 4.3;thyroid gland: 1.1 breast,esophagus: 0.3 LIPF HGL, HLAL ENSG00000182333 Lipase, gastric 10 88664441-88678814 Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at protein level HPA045930 Supported Tissue enriched Tissue enriched 82 stomach: 21780.0 duodenum: 267.0 LPL LIPD ENSG00000175445 Lipoprotein lipase 8 19901717-19967258 Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA048749 Approved Vesicles Urothelial cancer:6.07e-4 (unfavourable) Expressed in all Tissue enhanced adipose tissue: 974.6 parathyroid gland: 224.5 M6PR ENSG00000003056 Mannose-6-phosphate receptor (cation dependent) 12 8940363-8949955 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB034464, HPA040445 Approved Liver cancer:3.89e-4 (unfavourable) Expressed in all Expressed in all spleen: 178.5 MAOA ENSG00000189221 Monoamine oxidase A X 43654907-43746824 Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level CAB009437, HPA054807, HPA059299 Supported Validated Mitochondria Expressed in all Mixed small intestine: 253.2 MAOB ENSG00000069535 Monoamine oxidase B X 43766611-43882447 Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA002328, CAB037200 Supported Approved Nucleoli
Mitochondria Expressed in all Mixed seminal vesicle: 213.0 MAP1A MAP1L ENSG00000166963 Microtubule-associated protein 1A 15 43510958-43531620 FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA039063, HPA039064, HPA066488 Supported Approved Cytosol Thyroid cancer:1.09e-5 (unfavourable), Urothelial cancer:1.66e-5 (unfavourable), Renal cancer:6.59e-5 (unfavourable) Tissue enhanced Tissue enriched 9 cerebral cortex: 166.1 smooth muscle: 18.7 MAP2 MAP2A, MAP2B, MAP2C ENSG00000078018 Microtubule-associated protein 2 2 209424058-209734118 FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB001984, HPA008273, HPA012828 Supported Supported Supported Nucleoli
Cytosol Endometrial cancer:1.98e-6 (unfavourable) Tissue enhanced Tissue enriched 11 cerebral cortex: 297.4 thyroid gland: 27.8 MAP2K1 MAPKK1, MEK1, PRKMK1 ENSG00000169032 Mitogen-activated protein kinase kinase 1 15 66386817-66492312 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB003834, HPA026430 Approved Validated Plasma membrane
Cytosol Glioma:2.68e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 144.8 MAP2K2 MEK2, PRKMK2 ENSG00000126934 Mitogen-activated protein kinase kinase 2 19 4090321-4124129 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB003835, HPA051993 Supported Validated Cytosol Stomach cancer:5.43e-5 (favourable), Cervical cancer:3.72e-4 (favourable), Head and neck cancer:7.98e-4 (favourable) Expressed in all Expressed in all duodenum: 138.7 MAP4 ENSG00000047849 Microtubule-associated protein 4 3 47850690-48089272 FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA038149, HPA038150 Supported Supported Plasma membrane
Microtubules
Cytosol Liver cancer:1.82e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 242.6 MAPK1 ERK, ERK2, MAPK2, p41mapk, PRKM1, PRKM2 ENSG00000100030 Mitogen-activated protein kinase 1 22 21754500-21867680 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level HPA003995, CAB004229, HPA005700, HPA030069 Approved Liver cancer:4.95e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 132.8 MAPK11 p38-2, p38Beta, PRKM11, SAPK2 ENSG00000185386 Mitogen-activated protein kinase 11 22 50263713-50270767 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level CAB012961, HPA045069 Approved Approved Mitochondria Renal cancer:6.02e-6 (unfavourable) Expressed in all Mixed cerebral cortex: 27.8 MAPK3 ERK1, p44erk1, p44mapk, PRKM3 ENSG00000102882 Mitogen-activated protein kinase 3 16 30114105-30123506 Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB002683, HPA003995, HPA005700, HPA030069 Approved Approved Nucleoplasm Liver cancer:1.11e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 134.1 MAPT DDPAC, FLJ31424, FTDP-17, MAPTL, MGC138549, MSTD, MTBT1, MTBT2, PPND, PPP1R103, tau ENSG00000186868 Microtubule-associated protein tau 17 45894382-46028334 Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB000151, HPA048895, HPA069524, HPA069570 Supported Supported Nuclear speckles
Plasma membrane Group enriched Tissue enriched 8 cerebral cortex: 116.6 skeletal muscle: 13.7 MC2R ACTHR ENSG00000185231 Melanocortin 2 receptor (adrenocorticotropic hormone) 18 13882044-13915707 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level Not detected Tissue enriched 24 adrenal gland: 50.8 epididymis: 2.1 MET DFNB97, HGFR, RCCP2 ENSG00000105976 MET proto-oncogene, receptor tyrosine kinase 7 116672390-116798386 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB005282, CAB018577, HPA055607 Uncertain Supported Plasma membrane
Cytosol Pancreatic cancer:1.21e-7 (unfavourable), Head and neck cancer:6.75e-4 (unfavourable) Expressed in all Mixed placenta: 38.7 METAP2 MAP2, MNPEP, p67 ENSG00000111142 Methionyl aminopeptidase 2 12 95473520-95515839 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB013025, HPA019095 Supported Supported Plasma membrane
Cytosol Liver cancer:4.51e-6 (unfavourable) Expressed in all Expressed in all seminal vesicle: 141.9 MGAM MGA ENSG00000257335 Maltase-glucoamylase 7 141907813-142106747 Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA002270 Supported Renal cancer:6.16e-5 (favourable) Tissue enriched Tissue enhanced duodenum: 61.0;small intestine: 99.1 epididymis: 30.6 MME CALLA, CD10, NEP ENSG00000196549 Membrane metallo-endopeptidase 3 155024124-155183729 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB000013, HPA052583, HPA056072 Supported Mixed Tissue enhanced duodenum: 440.1;kidney: 381.4;small intestine: 410.3 prostate: 151.9 MMP1 CLG ENSG00000196611 Matrix metallopeptidase 1 11 102789920-102798160 Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA004920 Supported Vesicles Renal cancer:9.86e-10 (unfavourable), Liver cancer:4.22e-6 (unfavourable), Cervical cancer:4.66e-4 (unfavourable) Tissue enhanced Tissue enhanced appendix: 39.7;gallbladder: 126.6 urinary bladder: 30.2 MMP10 STMY2 ENSG00000166670 Matrix metallopeptidase 10 11 102770503-102780628 Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at protein level CAB002159 Uncertain Approved Plasma membrane
Cytosol Urothelial cancer:7.12e-4 (favourable) Tissue enhanced Tissue enriched 39 endometrium: 443.1 appendix: 11.3 MMP11 STMY3 ENSG00000099953 Matrix metallopeptidase 11 22 23768226-23784316 Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at protein level CAB002593, HPA068864 Approved Renal cancer:2.62e-4 (unfavourable) Expressed in all Group enriched 9 cervix, uterine: 30.9;endometrium: 122.3;placenta: 27.9 smooth muscle: 6.4 MMP12 HME ENSG00000262406 Matrix metallopeptidase 12 11 102862736-102875034 Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at protein level Liver cancer:1.42e-4 (unfavourable) Expressed in all Tissue enhanced appendix: 55.9;urinary bladder: 29.8 tonsil: 17.9 MMP13 CLG3 ENSG00000137745 Matrix metallopeptidase 13 11 102942995-102955734 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level Tissue enhanced Tissue enhanced lung: 1.5;urinary bladder: 1.4 appendix,testis: 0.3 MMP14 MT1-MMP ENSG00000157227 Matrix metallopeptidase 14 (membrane-inserted) 14 22836557-22849027 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB009918, HPA051432 Approved Approved Intermediate filaments
Cytosol Renal cancer:1.34e-4 (unfavourable), Ovarian cancer:9.48e-4 (unfavourable) Expressed in all Mixed endometrium: 236.1 MMP15 MT2-MMP, MTMMP2, SMCP-2 ENSG00000102996 Matrix metallopeptidase 15 (membrane-inserted) 16 58025566-58046901 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002611, HPA040390 Uncertain Approved Nucleoplasm
Plasma membrane
Cytosol Renal cancer:8.54e-8 (favourable), Urothelial cancer:3.08e-4 (favourable) Expressed in all Tissue enhanced thyroid gland: 69.9 duodenum: 39.8 MMP16 C8orf57, DKFZp761D112, MT3-MMP ENSG00000156103 Matrix metallopeptidase 16 (membrane-inserted) 8 88032009-88328025 Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA023693 Uncertain Approved Vesicles
Cytosol Tissue enhanced Tissue enhanced cerebral cortex: 9.6 gallbladder: 4.2 MMP17 MT4-MMP ENSG00000198598 Matrix metallopeptidase 17 (membrane-inserted) 12 131828393-131851783 Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level Tissue enriched Tissue enhanced cerebral cortex: 24.1 skin: 8.2 MMP19 MMP18, RASI-1 ENSG00000123342 Matrix metallopeptidase 19 12 55835433-55842966 Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at protein level HPA070804 Approved Endoplasmic reticulum
Vesicles Renal cancer:8.56e-9 (unfavourable) Expressed in all Tissue enhanced adipose tissue: 63.1;gallbladder: 97.5 placenta: 27.9 MMP2 CLG4, CLG4A, TBE-1 ENSG00000087245 Matrix metallopeptidase 2 16 55389700-55506691 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA001939, CAB002788 Approved Uncertain Vesicles
Cytosol Expressed in all Tissue enhanced gallbladder: 1688.5 urinary bladder: 944.6 MMP20 ENSG00000137674 Matrix metallopeptidase 20 11 102576835-102625332 Disease related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at protein level Not detected Group enriched 5 breast: 1.2;testis: 1.1 tonsil: 0.2 MMP21 ENSG00000154485 Matrix metallopeptidase 21 10 125766453-125775821 Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at protein level Not detected Tissue enriched 27 epididymis: 58.2 ovary: 2.1 MMP23B MIFR, MIFR-1, MMP22 ENSG00000189409 Matrix metallopeptidase 23B 1 1632095-1701810 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level Tissue enhanced Mixed placenta: 4.4 MMP24 MT5-MMP ENSG00000125966 Matrix metallopeptidase 24 (membrane-inserted) 20 35226654-35277000 Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at transcript level HPA049280 Approved Nucleoli
Plasma membrane Renal cancer:8.17e-11 (favourable) Mixed Tissue enhanced cerebral cortex: 10.6 lung: 7.1 MMP25 MMP20, MMPL1, MT6-MMP ENSG00000008516 Matrix metallopeptidase 25 16 3046681-3060726 Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB025177 Uncertain Head and neck cancer:1.09e-5 (favourable) Tissue enhanced Tissue enhanced appendix: 23.9;bone marrow: 24.7;spleen: 21.1 adipose tissue: 6.3 MMP26 endometase, MGC126590, MGC126592 ENSG00000167346 Matrix metallopeptidase 26 11 4704927-4992429 Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at transcript level Group enriched Tissue enriched 64 endometrium: 23.8 prostate,testis: 0.3 MMP27 ENSG00000137675 Matrix metallopeptidase 27 11 102691487-102705806 Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at protein level HPA069097 Approved Not detected Group enriched 5 breast: 6.0;skin: 2.8 bone marrow: 0.8 MMP28 EPILYSIN, MM28, MMP-25, MMP-28 ENSG00000271447 Matrix metallopeptidase 28 17 35756249-35795707 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level Pancreatic cancer:6.28e-6 (unfavourable) Mixed Tissue enhanced testis: 6.4 adipose tissue: 4.2 MMP3 STMY, STMY1 ENSG00000149968 Matrix metallopeptidase 3 11 102835801-102843803 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA007875 Uncertain Approved Vesicles Pancreatic cancer:4.09e-4 (unfavourable), Cervical cancer:9.73e-4 (unfavourable) Tissue enhanced Tissue enhanced appendix: 26.9;endometrium: 58.7 urinary bladder: 9.2 MMP7 MPSL1, PUMP-1 ENSG00000137673 Matrix metallopeptidase 7 11 102520508-102530753 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB025869, HPA051358 Supported Approved Nucleoplasm
Vesicles Liver cancer:2.53e-4 (unfavourable), Lung cancer:3.38e-4 (unfavourable) Expressed in all Tissue enhanced gallbladder: 824.4 breast: 201.5 MMP8 CLG1 ENSG00000118113 Matrix metallopeptidase 8 11 102711795-102727050 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA021221, HPA022935 Supported Tissue enriched Tissue enriched 103 bone marrow: 336.3 endometrium: 3.2 MMP9 CLG4B ENSG00000100985 Matrix metallopeptidase 9 20 46008908-46016561 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB000348, HPA001238, HPA063909, CAB068199, CAB068200, CAB068201 Supported Approved Cytosol Renal cancer:4.05e-5 (unfavourable), Endometrial cancer:2.55e-4 (favourable), Liver cancer:7.19e-4 (unfavourable) Expressed in all Tissue enhanced bone marrow: 253.0;lymph node: 119.4 appendix: 85.4 MPL CD110, TPOR ENSG00000117400 MPL proto-oncogene, thrombopoietin receptor 1 43337807-43352772 Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA007619 Uncertain Plasma membrane Not detected Tissue enhanced testis: 1.8 ovary: 1.3 MR1 HLALS ENSG00000153029 Major histocompatibility complex, class I-related 1 181033425-181061938 FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA048304 Supported Plasma membrane Expressed in all Mixed thyroid gland: 28.1 MS4A1 B1, Bp35, CD20, MS4A2 ENSG00000156738 Membrane-spanning 4-domains, subfamily A, member 1 11 60455752-60470760 CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB000015, HPA014341, HPA014391 Supported Breast cancer:4.34e-5 (favourable) Mixed Group enriched 15 appendix: 249.3;lymph node: 780.6;spleen: 476.2;tonsil: 821.5 urinary bladder: 39.8 MS4A2 APY, FCER1B, IGER, MS4A1 ENSG00000149534 Membrane-spanning 4-domains, subfamily A, member 2 11 60088261-60098466 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA059967 Supported Mixed Tissue enhanced lung: 24.8 gallbladder: 18.5 MTNR1A MEL-1A-R ENSG00000168412 Melatonin receptor 1A 4 186533655-186555567 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level Not detected Tissue enhanced kidney: 2.2;testis: 1.9 colon: 1.2 MTNR1B ENSG00000134640 Melatonin receptor 1B 11 92969720-92985066 FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Not detected Tissue enhanced placenta: 1.4 testis: 0.8 MTOR FLJ44809, FRAP, FRAP1, FRAP2, RAFT1, RAPT1 ENSG00000198793 Mechanistic target of rapamycin (serine/threonine kinase) 1 11106535-11262507 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB069425, HPA071227 Approved Approved Vesicles
Cytosol Renal cancer:1.49e-5 (favourable) Expressed in all Expressed in all testis: 62.0 MTR cblG ENSG00000116984 5-methyltetrahydrofolate-homocysteine methyltransferase 1 236795281-236903981 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA044474 Supported Cytosol Thyroid cancer:5.75e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 28.4 MTTP ABL, MTP ENSG00000138823 Microsomal triglyceride transfer protein 4 99563761-99623999 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA051170, HPA054862 Uncertain Approved Cytosol Tissue enriched Group enriched 17 duodenum: 243.0;liver: 133.9;small intestine: 299.0 testis: 13.5 MUT ENSG00000146085 Methylmalonyl CoA mutase 6 49430360-49463191 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA035971, HPA035972 Supported Approved Mitochondria
Cytosol Renal cancer:8.71e-13 (favourable) Expressed in all Expressed in all liver: 104.1 NFKB1 KBF1, NF-kappaB, NF-kB1, NFkappaB, NFKB-p50, p105, p50 ENSG00000109320 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 4 102501329-102617302 Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins, Transcription factors Evidence at protein level CAB004031, HPA027305 Supported Supported Nucleoplasm
Cytosol Renal cancer:1.76e-4 (favourable) Expressed in all Expressed in all bone marrow: 57.0 NISCH I-1, IRAS, KIAA0975 ENSG00000010322 Nischarin 3 52455118-52493071 FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA023189 Approved Pancreatic cancer:1.91e-4 (favourable) Expressed in all Expressed in all testis: 96.0 NNMT ENSG00000166741 Nicotinamide N-methyltransferase 11 114257787-114313285 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA059180 Approved Approved Golgi apparatus Renal cancer:1.02e-6 (unfavourable), Stomach cancer:1.75e-4 (unfavourable), Head and neck cancer:2.07e-4 (unfavourable) Expressed in all Tissue enhanced liver: 197.4 adipose tissue: 106.7 NOS2 HEP-NOS, iNOS, NOS, NOS2A ENSG00000007171 Nitric oxide synthase 2, inducible 17 27756766-27800499 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002014 Approved Tissue enhanced Group enriched 5 appendix: 19.6;colon: 7.2;duodenum: 12.6;rectum: 10.0;small intestine: 24.6;urinary bladder: 6.7 smooth muscle: 2.5 NOS3 ECNOS, eNOS ENSG00000164867 Nitric oxide synthase 3 (endothelial cell) 7 150990995-151014588 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002168 Supported Renal cancer:3.63e-4 (unfavourable) Expressed in all Tissue enriched 7 spleen: 73.1 adipose tissue: 10.7 NOXO1 P41NOXA, P41NOXB, P41NOXC, SH3PXD5, SNX28 ENSG00000196408 NADPH oxidase organizer 1 16 1978917-1984192 FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA071540 Supported Not detected Tissue enhanced appendix: 6.6;colon: 7.5;rectum: 6.7 duodenum: 3.4 NPC1L1 ENSG00000015520 NPC1-like 1 7 44512535-44541315 FDA approved drug targets, Predicted membrane proteins Evidence at protein level CAB070127, CAB070128 Supported Group enriched Tissue enhanced duodenum: 58.7;small intestine: 59.3 liver: 14.2 NPR1 ANPa, ANPRA, GUCY2A, NPRA ENSG00000169418 Natriuretic peptide receptor 1 1 153678637-153693992 Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA031087 Approved Nucleus
Nucleoli
Plasma membrane Pancreatic cancer:2.49e-4 (favourable), Endometrial cancer:3.97e-4 (unfavourable) Expressed in all Tissue enhanced adipose tissue: 71.8;fallopian tube: 57.6 placenta: 25.2 NPR2 AMDM, ANPb, ANPRB, GUCY2B, NPRB ENSG00000159899 Natriuretic peptide receptor 2 9 35792154-35809732 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Expressed in all Mixed endometrium: 30.7 NR1I2 BXR, ONR1, PAR2, PXR, SXR ENSG00000144852 Nuclear receptor subfamily 1, group I, member 2 3 119780484-119818485 FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA029309, HPA055121, HPA073926 Validated Nucleoplasm Group enriched Group enriched 12 colon: 9.3;duodenum: 23.2;gallbladder: 6.0;liver: 19.7;rectum: 9.4;small intestine: 26.3 stomach: 1.3 NR3C1 GR, GRL ENSG00000113580 Nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) 5 143277931-143435512 Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA004248, CAB010435 Supported Validated Nucleoplasm
Mitochondria
Cytosol Renal cancer:1.72e-6 (unfavourable), Endometrial cancer:3.64e-5 (unfavourable) Expressed in all Expressed in all placenta: 66.4 NR3C2 MLR, MR ENSG00000151623 Nuclear receptor subfamily 3, group C, member 2 4 148078762-148444698 Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB009155, HPA074979 Supported Approved Nucleoplasm Renal cancer:3.10e-11 (favourable) Mixed Mixed thyroid gland: 32.1 NTRK1 MTC, TRK, TRKA ENSG00000198400 Neurotrophic tyrosine kinase, receptor, type 1 1 156815640-156881850 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level CAB004606, HPA035799, HPA076570 Approved Uncertain Vesicles
Cytosol Tissue enhanced Tissue enriched 6 adrenal gland: 9.6 testis: 1.6 NTSR2 NTR2 ENSG00000169006 Neurotensin receptor 2 2 11658178-11670164 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level Tissue enriched Tissue enriched 25 cerebral cortex: 25.1 ovary: 1.0 ODC1 ODC ENSG00000115758 Ornithine decarboxylase 1 2 10439968-10448504 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA001536, CAB035996 Approved Approved Plasma membrane
Cytosol Liver cancer:3.07e-5 (unfavourable) Expressed in all Expressed in all testis: 240.7 OPRD1 ENSG00000116329 Opioid receptor, delta 1 1 28812142-28871267 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA013744 Uncertain Tissue enhanced Tissue enhanced cerebral cortex: 2.6 adrenal gland: 0.8 OPRK1 KOR, OPRK ENSG00000082556 Opioid receptor, kappa 1 8 53225716-53251697 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level CAB022595 Uncertain Tissue enhanced Group enriched 7 cerebral cortex: 3.6;prostate: 3.2;testis: 1.8 placenta,skeletal muscle: 0.3 OPRM1 MOR1 ENSG00000112038 Opioid receptor, mu 1 6 154010496-154246867 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA014509, HPA067435 Supported Supported Not detected Tissue enhanced testis: 4.2 adrenal gland,esophagus: 1.2 OXTR ENSG00000180914 Oxytocin receptor 3 8750408-8769628 FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Mixed Tissue enriched 11 breast: 65.6 fallopian tube: 6.0 P2RY12 HORK3, P2Y12, SP1999 ENSG00000169313 Purinergic receptor P2Y, G-protein coupled, 12 3 151337380-151384812 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA013796, HPA014518 Supported Tissue enriched Tissue enriched 6 cerebral cortex: 84.0 lymph node: 13.3 P2RY2 P2U ENSG00000175591 Purinergic receptor P2Y, G-protein coupled, 2 11 73218298-73236352 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level CAB022642 Uncertain Uncertain Cytosol Pancreatic cancer:2.19e-5 (unfavourable) Mixed Tissue enhanced esophagus: 19.0 skeletal muscle: 14.9 PAH PH ENSG00000171759 Phenylalanine hydroxylase 12 102836885-102958410 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA028407, HPA031642 Supported Approved Endoplasmic reticulum
Vesicles Liver cancer:4.30e-4 (favourable) Tissue enriched Tissue enhanced kidney: 500.3;liver: 720.9 gallbladder: 126.2 PARP1 ADPRT, PARP, PPOL ENSG00000143799 Poly (ADP-ribose) polymerase 1 1 226360691-226408079 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB000147, CAB003839, CAB003840, HPA045168, CAB075726, CAB075727 Supported Validated Nucleus Renal cancer:1.35e-5 (unfavourable), Liver cancer:3.40e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 195.1 PARP2 ADPRTL2 ENSG00000129484 Poly (ADP-ribose) polymerase 2 14 20343582-20357905 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA052003 Approved Approved Nucleus
Nucleoli Liver cancer:6.48e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 46.5 PARP3 ADPRT3, ADPRTL3, hPARP-3, IRT1, pADPRT-3 ENSG00000041880 Poly (ADP-ribose) polymerase family, member 3 3 51942345-51948867 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA067657 Supported Approved Nucleoli
Cytosol Renal cancer:1.25e-8 (favourable), Breast cancer:6.39e-5 (favourable) Expressed in all Mixed parathyroid gland: 52.0 PCSK9 FH3, HCHOLA3, NARC-1 ENSG00000169174 Proprotein convertase subtilisin/kexin type 9 1 55039548-55064852 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level Urothelial cancer:2.40e-4 (unfavourable) Mixed Tissue enhanced liver: 6.1;lung: 11.1 colon: 3.5 PDCD1 CD279, hSLE1, PD-1, PD1, SLEB2 ENSG00000188389 Programmed cell death 1 2 241849881-241858908 CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA035981, CAB038418 Supported Renal cancer:3.48e-7 (unfavourable), Endometrial cancer:9.44e-5 (favourable) Mixed Tissue enhanced lymph node: 12.2 appendix: 3.4 PDE10A ENSG00000112541 Phosphodiesterase 10A 6 165327287-165986603 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level CAB045998, HPA047200 Supported Renal cancer:4.44e-7 (unfavourable) Mixed Tissue enhanced thyroid gland: 14.4 testis: 12.2 PDE3A CGI-PDE ENSG00000172572 Phosphodiesterase 3A, cGMP-inhibited 12 20369245-20684381 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA014492 Uncertain Supported Cytosol Renal cancer:1.72e-6 (unfavourable) Expressed in all Tissue enhanced heart muscle: 38.3 placenta: 31.1 PDE4A DPDE2 ENSG00000065989 Phosphodiesterase 4A, cAMP-specific 19 10416773-10469631 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level CAB017632, HPA043310, HPA076091 Uncertain Supported Plasma membrane Expressed in all Mixed parathyroid gland: 33.4 PDE4B DPDE4 ENSG00000184588 Phosphodiesterase 4B, cAMP-specific 1 65792514-66374579 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA003005 Uncertain Renal cancer:5.04e-4 (unfavourable) Expressed in all Mixed cerebral cortex: 67.2 PDE4C DPDE1 ENSG00000105650 Phosphodiesterase 4C, cAMP-specific 19 18207961-18255419 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA048975 Approved Mixed Mixed endometrium: 7.4 PDE4D DPDE3 ENSG00000113448 Phosphodiesterase 4D, cAMP-specific 5 58969038-60522120 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA045895 Approved Approved Nuclear membrane
Plasma membrane
Cytosol Renal cancer:4.00e-5 (favourable) Mixed Mixed bone marrow: 46.6 PDE5A ENSG00000138735 Phosphodiesterase 5A, cGMP-specific 4 119494395-119628991 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA004729, HPA012873 Approved Approved Cytosol Urothelial cancer:1.17e-4 (unfavourable), Cervical cancer:5.20e-4 (favourable) Expressed in all Expressed in all prostate: 90.8 PDE7A HCP1 ENSG00000205268 Phosphodiesterase 7A 8 65717510-65842322 Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB018770, HPA027340 Approved Renal cancer:1.35e-4 (unfavourable), Liver cancer:5.64e-4 (unfavourable) Expressed in all Expressed in all lymph node: 69.7 PDE7B ENSG00000171408 Phosphodiesterase 7B 6 135851696-136195574 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA023967 Uncertain Approved Nucleoplasm Renal cancer:1.59e-4 (favourable) Mixed Mixed ovary: 16.1 PDE8A HsT19550 ENSG00000073417 Phosphodiesterase 8A 15 84980440-85139145 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA007722 Approved Approved Golgi apparatus Expressed in all Expressed in all parathyroid gland: 29.6 PDE8B ENSG00000113231 Phosphodiesterase 8B 5 77210449-77429807 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA036911, HPA036912 Supported Approved Nucleoplasm
Cytosol Tissue enriched Tissue enriched 5 thyroid gland: 292.2 cerebral cortex: 53.2 PDGFRA CD140a, GAS9, PDGFR2 ENSG00000134853 Platelet-derived growth factor receptor, alpha polypeptide 4 54229097-54298247 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level HPA004947, CAB018143 Supported Supported Nucleus
Plasma membrane
Cell Junctions Renal cancer:9.79e-6 (unfavourable), Head and neck cancer:9.33e-4 (favourable) Expressed in all Expressed in all ovary: 222.0 PDGFRB CD140b, JTK12, PDGFR, PDGFR1 ENSG00000113721 Platelet-derived growth factor receptor, beta polypeptide 5 150113837-150155872 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB003842, CAB018144, HPA028499 Approved Approved Vesicles
Cytosol Renal cancer:5.87e-8 (unfavourable), Urothelial cancer:8.11e-4 (unfavourable) Expressed in all Mixed gallbladder: 194.6 PDXK C21orf124, C21orf97, FLJ21324, FLJ31940, MGC15873, PKH, PNK, PRED79 ENSG00000160209 Pyridoxal (pyridoxine, vitamin B6) kinase 21 43719094-43762307 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA030196, HPA030197, HPA030198, CAB033918 Approved Validated Nucleus Expressed in all Expressed in all cerebral cortex: 47.6 PGF D12S1900, PGFL, PLGF, PlGF-2, SHGC-10760 ENSG00000119630 Placental growth factor 14 74941834-74955784 Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level HPA041624 Approved Nucleoplasm
Mitochondria
Cytosol Renal cancer:1.33e-6 (unfavourable), Liver cancer:1.40e-4 (unfavourable) Expressed in all Tissue enhanced placenta: 70.9;thyroid gland: 64.4 cervix, uterine: 29.9 PGR NR3C3, PR ENSG00000082175 Progesterone receptor 11 101029624-101130524 Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB000068, HPA004751, HPA008428, HPA017176, CAB055100 Supported Endometrial cancer:5.76e-8 (favourable) Group enriched Group enriched 6 cervix, uterine: 95.8;endometrium: 171.3;fallopian tube: 52.8;smooth muscle: 113.5 ovary: 19.4 PLA2G1B PLA2, PLA2A, PPLA2 ENSG00000170890 Phospholipase A2, group IB (pancreas) 12 120322111-120327789 Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB022329, HPA047822, HPA060803 Supported Validated Cytosol Tissue enriched Tissue enriched 245 pancreas: 23848.8 ovary: 97.3 PLA2G2A PLA2B, PLA2L ENSG00000188257 Phospholipase A2, group IIA (platelets, synovial fluid) 1 19975431-19980416 Enzymes, FDA approved drug targets, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level HPA015236 Supported Uncertain Nucleus
Nucleoli Melanoma:1.49e-4 (favourable) Expressed in all Tissue enhanced colon: 111.4;rectum: 180.4;small intestine: 238.2 duodenum: 87.9 PLA2G4A cPLA2-alpha, PLA2G4 ENSG00000116711 Phospholipase A2, group IVA (cytosolic, calcium-dependent) 1 186828953-186988981 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB010050, HPA050062, HPA054206 Approved Supported Cytosol Endometrial cancer:2.85e-4 (favourable), Breast cancer:9.07e-4 (favourable) Mixed Tissue enhanced parathyroid gland: 196.9 seminal vesicle: 67.6 PLA2G6 iPLA2, iPLA2beta, NBIA2, PARK14, PNPLA9 ENSG00000184381 Phospholipase A2, group VI (cytosolic, calcium-independent) 22 38111495-38205690 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins Evidence at protein level HPA001171 Approved Approved Microtubule organizing center
Cytosol Urothelial cancer:1.55e-4 (favourable), Cervical cancer:7.29e-4 (favourable) Expressed in all Expressed in all testis: 60.3 PLAT ENSG00000104368 Plasminogen activator, tissue 8 42175233-42207724 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA003412, CAB009335 Supported Approved Actin filaments Renal cancer:4.95e-4 (unfavourable), Breast cancer:7.57e-4 (favourable) Expressed in all Tissue enhanced parathyroid gland: 695.5 urinary bladder: 141.1 PLAU UPA, URK ENSG00000122861 Plasminogen activator, urokinase 10 73909177-73917497 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA008719 Approved Approved Plasma membrane
Cytosol Pancreatic cancer:1.32e-4 (unfavourable), Head and neck cancer:2.70e-4 (unfavourable), Endometrial cancer:3.38e-4 (favourable), Renal cancer:3.51e-4 (unfavourable), Lung cancer:4.04e-4 (unfavourable) Expressed in all Expressed in all appendix: 61.3 PLAUR CD87, UPAR, URKR ENSG00000011422 Plasminogen activator, urokinase receptor 19 43646095-43670547 Cancer-related genes, CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA050843, CAB073533 Uncertain Supported Plasma membrane Renal cancer:7.83e-9 (unfavourable), Lung cancer:2.33e-5 (unfavourable) Expressed in all Expressed in all bone marrow: 429.4 PLCL1 PLC-L, PLCE, PLCL, PPP1R127, PRIP ENSG00000115896 Phospholipase C-like 1 2 197804702-198572581 FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA031849 Approved Renal cancer:3.91e-7 (favourable) Mixed Mixed kidney: 34.0 PLG ENSG00000122194 Plasminogen 6 160702238-160753315 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB000668, CAB016678, HPA021602, HPA048823, HPA053770 Supported Uncertain Vesicles Renal cancer:4.22e-4 (favourable) Tissue enriched Tissue enriched 6 liver: 1748.3 kidney: 310.9 PLIN3 M6PRBP1, PP17, TIP47 ENSG00000105355 Perilipin 3 19 4838341-4867768 FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA006427, HPA066538 Uncertain Validated Lipid droplets
Cytosol Renal cancer:9.15e-7 (unfavourable), Lung cancer:7.67e-6 (unfavourable), Liver cancer:3.27e-5 (unfavourable), Endometrial cancer:2.62e-4 (favourable) Expressed in all Expressed in all esophagus: 116.2 PNLIP PL ENSG00000175535 Pancreatic lipase 10 116545931-116567855 Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA062430, HPA062494 Supported Tissue enriched Tissue enriched 324 pancreas: 93652.7 ovary: 288.6 PNP NP, PUNP ENSG00000198805 Purine nucleoside phosphorylase 14 20468954-20477094 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA001625 Supported Renal cancer:2.24e-4 (favourable), Liver cancer:4.43e-4 (unfavourable) Expressed in all Expressed in all epididymis: 686.0 POLA1 NSX, p180, POLA ENSG00000101868 Polymerase (DNA directed), alpha 1, catalytic subunit X 24693919-24996986 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA002947, CAB012274 Supported Supported Nucleoplasm
Cytosol Liver cancer:4.80e-5 (unfavourable) Expressed in all Mixed lymph node: 8.8 POLB ENSG00000070501 Polymerase (DNA directed), beta 8 42338454-42371808 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB011616, HPA049104 Supported Approved Vesicles Renal cancer:2.15e-5 (unfavourable), Endometrial cancer:1.46e-4 (unfavourable), Urothelial cancer:5.65e-4 (favourable) Expressed in all Expressed in all testis: 92.3 POLE POLE1 ENSG00000177084 Polymerase (DNA directed), epsilon, catalytic subunit 12 132623753-132687365 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA058210, HPA067385 Validated Nucleus
Plasma membrane Renal cancer:3.19e-8 (unfavourable), Melanoma:1.44e-4 (unfavourable) Expressed in all Expressed in all testis: 22.0 POLE2 DPE2 ENSG00000100479 Polymerase (DNA directed), epsilon 2, accessory subunit 14 49643555-49688422 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA027555 Uncertain Supported Nucleoplasm
Nuclear bodies
Vesicles Expressed in all Mixed bone marrow: 10.8 POLE3 CHARAC17, CHRAC17, p17, Ybl1 ENSG00000148229 Polymerase (DNA directed), epsilon 3, accessory subunit 9 113407235-113410672 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA047945 Uncertain Approved Nucleus
Nucleoli Liver cancer:8.35e-4 (unfavourable) Expressed in all Expressed in all testis: 76.2 POLE4 p12 ENSG00000115350 Polymerase (DNA-directed), epsilon 4, accessory subunit 2 74958492-74970128 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA054979, HPA071815 Approved Approved Nucleus
Cytosol Liver cancer:6.49e-4 (unfavourable) Expressed in all Expressed in all cervix, uterine: 12.7 PPARA hPPAR, NR1C1, PPAR ENSG00000186951 Peroxisome proliferator-activated receptor alpha 22 46150521-46243756 FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA058901, HPA067049 Supported Nucleus Renal cancer:4.39e-9 (favourable) Expressed in all Expressed in all kidney: 24.0 PPARD FAAR, NR1C2, NUC1, NUCII ENSG00000112033 Peroxisome proliferator-activated receptor delta 6 35342558-35428191 FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB017635 Approved Liver cancer:4.57e-4 (unfavourable) Expressed in all Expressed in all placenta: 40.1 PPARG NR1C3, PPARG1, PPARG2, PPARgamma ENSG00000132170 Peroxisome proliferator-activated receptor gamma 3 12287368-12434356 Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB004282, HPA051239, HPA063663 Approved Validated Nucleus
Vesicles Renal cancer:1.59e-8 (favourable), Liver cancer:3.41e-5 (unfavourable), Urothelial cancer:5.52e-5 (favourable) Expressed in all Tissue enhanced adipose tissue: 172.8 placenta: 58.6 PPP3R2 PPP3RL ENSG00000188386 Protein phosphatase 3, regulatory subunit B, beta 9 101591615-101595001 FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA047157 Uncertain Approved Plasma membrane
Cytosol Not detected Tissue enriched 755 testis: 75.4 all non-specific tissues: 0.0 PRDX5 ACR1, AOEB166, B166, MGC117264, MGC142283, MGC142285, PLP, PMP20, PRDX6, PRXV, SBBI10 ENSG00000126432 Peroxiredoxin 5 11 64318088-64321811 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB008661, HPA037915, HPA037916 Supported Validated Mitochondria
Cytosol Renal cancer:1.24e-5 (favourable) Expressed in all Expressed in all fallopian tube: 599.3 PRKAA1 AMPKa1 ENSG00000132356 Protein kinase, AMP-activated, alpha 1 catalytic subunit 5 40759379-40798374 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level CAB005050, HPA035409, HPA064946 Supported Supported Nuclear speckles Expressed in all Expressed in all testis: 74.4 PRKAB1 ENSG00000111725 Protein kinase, AMP-activated, beta 1 non-catalytic subunit 12 119667753-119681630 FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA004247, CAB005058 Supported Approved Nucleoplasm
Cytosol Renal cancer:5.40e-9 (favourable), Endometrial cancer:8.66e-4 (favourable) Expressed in all Expressed in all kidney: 53.7 PRLR ENSG00000113494 Prolactin receptor 5 35048756-35230589 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Tissue enriched Tissue enhanced placenta: 70.3 kidney: 32.9 PROC ENSG00000115718 Protein C (inactivator of coagulation factors Va and VIIIa) 2 127418427-127429246 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA005550, CAB016721, CAB016792 Supported Tissue enriched Tissue enriched 12 liver: 139.9 kidney: 12.0 PROS1 PROS ENSG00000184500 Protein S (alpha) 3 93873033-93974066 Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA007724, HPA023974 Supported Urothelial cancer:4.42e-5 (unfavourable), Stomach cancer:8.35e-4 (unfavourable) Expressed in all Tissue enhanced liver: 177.6 heart muscle: 75.3 PSMB1 HC5, PMSB1 ENSG00000008018 Proteasome subunit beta 1 6 170535117-170553341 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA029635, HPA029637, CAB033911 Supported Supported Nucleus Renal cancer:3.76e-6 (unfavourable) Expressed in all Expressed in all epididymis: 314.7 PSMB10 beta2i, LMP10, MECL1, MGC1665 ENSG00000205220 Proteasome subunit beta 10 16 67934502-67937087 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA030224, HPA030225, CAB034384 Supported Supported Vesicles
Cytosol Urothelial cancer:5.44e-4 (favourable) Expressed in all Expressed in all lymph node: 92.6 PSMB2 HC7-I ENSG00000126067 Proteasome subunit beta 2 1 35599544-35641844 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA026322, HPA026324 Approved Validated Nucleoplasm Liver cancer:3.49e-7 (unfavourable), Renal cancer:2.80e-6 (unfavourable) Expressed in all Expressed in all placenta: 43.0 PSMB5 MB1, X ENSG00000100804 Proteasome subunit beta 5 14 23016543-23035230 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA049518, HPA061796 Approved Supported Nucleus
Centrosome Liver cancer:2.90e-5 (unfavourable), Ovarian cancer:1.08e-4 (favourable), Head and neck cancer:2.85e-4 (unfavourable), Urothelial cancer:4.73e-4 (unfavourable) Expressed in all Expressed in all epididymis: 139.6 PSMB8 beta5i, D6S216E, LMP7, PSMB5i, RING10 ENSG00000204264 Proteasome subunit beta 8 6 32840717-32844703 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA046995, HPA050327 Supported Approved Vesicles
Cytokinetic bridge Breast cancer:5.08e-4 (favourable), Endometrial cancer:7.16e-4 (favourable) Expressed in all Mixed lymph node: 23.3 PSMB9 beta1i, LMP2, PSMB6i, RING12 ENSG00000240065 Proteasome subunit beta 9 6 32844136-32859585 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB015180, HPA042818, HPA053280 Supported Supported Cytosol Renal cancer:1.33e-4 (unfavourable) Expressed in all Mixed spleen: 39.9 PSMD1 P112, Rpn2, S1 ENSG00000173692 Proteasome 26S subunit, non-ATPase 1 2 231056864-231172827 FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB021092, HPA036736, HPA036737 Approved Approved Nucleoplasm
Actin filaments Liver cancer:8.63e-12 (unfavourable), Lung cancer:2.34e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 200.6 PSMD2 MGC14274, P97, Rpn1, S2, TRAP2 ENSG00000175166 Proteasome 26S subunit, non-ATPase 2 3 184298709-184309054 FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA045192 Approved Liver cancer:6.63e-7 (unfavourable), Lung cancer:1.55e-4 (unfavourable), Head and neck cancer:9.98e-4 (unfavourable) Expressed in all Expressed in all testis: 163.1 PTGER1 EP1 ENSG00000160951 Prostaglandin E receptor 1 (subtype EP1), 42kDa 19 14472466-14475362 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at transcript level Tissue enhanced Tissue enhanced kidney: 2.9;spleen: 2.6 appendix,lung: 0.7 PTGER2 EP2 ENSG00000125384 Prostaglandin E receptor 2 (subtype EP2), 53kDa 14 52314305-52328606 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level Renal cancer:4.16e-4 (unfavourable) Mixed Mixed cervix, uterine: 27.3 PTGER3 EP3 ENSG00000050628 Prostaglandin E receptor 3 (subtype EP3) 1 70852353-71047808 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA010689 Uncertain Renal cancer:3.50e-4 (unfavourable) Group enriched Group enriched 7 adipose tissue: 58.5;endometrium: 114.7;kidney: 87.6;smooth muscle: 103.9 skin: 14.0 PTGER4 EP4 ENSG00000171522 Prostaglandin E receptor 4 (subtype EP4) 5 40679498-40693735 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA011226, HPA012756 Approved Urothelial cancer:2.48e-4 (favourable) Expressed in all Expressed in all bone marrow: 48.1 PTGFR FP ENSG00000122420 Prostaglandin F receptor (FP) 1 78303884-78539749 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level Mixed Tissue enhanced endometrium: 30.3;smooth muscle: 25.4 urinary bladder: 13.3 PTGIR IP ENSG00000160013 Prostaglandin I2 (prostacyclin) receptor (IP) 19 46620468-46625118 FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Renal cancer:2.09e-8 (unfavourable), Testis cancer:1.74e-4 (unfavourable) Mixed Tissue enhanced lung: 14.0 appendix: 8.4 PTGIS CYP8A1, PGIS ENSG00000124212 Prostaglandin I2 (prostacyclin) synthase 20 49503874-49568146 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB009517, HPA014193 Approved Renal cancer:4.74e-8 (unfavourable), Urothelial cancer:9.99e-5 (unfavourable) Expressed in all Mixed fallopian tube: 77.4 PTGS1 COX1, PGHS-1, PTGHS ENSG00000095303 Prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) 9 122370530-122395703 Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA002834, CAB020315 Supported Supported Golgi apparatus
Vesicles Renal cancer:8.68e-4 (unfavourable), Urothelial cancer:9.35e-4 (unfavourable) Expressed in all Tissue enhanced skin: 161.9 esophagus: 85.8 PTGS2 COX2 ENSG00000073756 Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) 1 186671791-186680427 Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at protein level CAB000113, HPA001335 Approved Supported Endoplasmic reticulum Renal cancer:9.79e-4 (unfavourable) Mixed Tissue enhanced seminal vesicle: 178.8 cervix, uterine: 98.8 PTH2R PTHR2 ENSG00000144407 Parathyroid hormone 2 receptor 2 208359714-208854503 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA010655 Approved Tissue enhanced Mixed bone marrow: 2.9 QPRT QPRTase ENSG00000103485 Quinolinate phosphoribosyltransferase 16 29679008-29698699 Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA011887 Approved Breast cancer:5.10e-5 (unfavourable), Glioma:7.45e-4 (unfavourable) Expressed in all Expressed in all kidney: 111.8 RAF1 c-Raf, CRAF, Raf-1 ENSG00000132155 Raf-1 proto-oncogene, serine/threonine kinase 3 12583601-12664226 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level HPA002640, CAB019291 Approved Approved Nuclear speckles Expressed in all Expressed in all parathyroid gland: 100.1 RAMP1 ENSG00000132329 Receptor (G protein-coupled) activity modifying protein 1 2 237858893-237912114 FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA057814 Approved Nucleoplasm
Nuclear membrane Stomach cancer:1.68e-4 (unfavourable), Liver cancer:7.61e-4 (favourable) Expressed in all Tissue enhanced endometrium: 233.7 smooth muscle: 169.4 RAMP2 ENSG00000131477 Receptor (G protein-coupled) activity modifying protein 2 17 42758447-42763041 FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA052020 Approved Vesicles Expressed in all Mixed lung: 179.1 RAMP3 ENSG00000122679 Receptor (G protein-coupled) activity modifying protein 3 7 45157791-45186302 FDA approved drug targets, Predicted membrane proteins Evidence at protein level Liver cancer:2.50e-6 (favourable), Cervical cancer:2.89e-4 (favourable) Expressed in all Tissue enhanced lung: 120.5 thyroid gland: 66.2 RARA NR1B1, RAR ENSG00000131759 Retinoic acid receptor, alpha 17 40309192-40357643 Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA058282 Supported Nucleus
Cytosol Endometrial cancer:2.60e-4 (favourable) Expressed in all Expressed in all gallbladder: 68.9 RARB HAP, NR1B2, RRB2 ENSG00000077092 Retinoic acid receptor, beta 3 25174332-25597932 Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB002617, HPA004174 Supported Validated Nucleoplasm Renal cancer:3.43e-5 (favourable) Expressed in all Mixed placenta: 20.5 RARG NR1B3, RARC ENSG00000172819 Retinoic acid receptor, gamma 12 53210567-53232980 Cancer-related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA053883 Supported Supported Nucleoplasm Renal cancer:3.08e-6 (unfavourable), Endometrial cancer:3.68e-6 (unfavourable) Expressed in all Tissue enhanced skin: 143.7 esophagus: 77.6 REN ENSG00000143839 Renin 1 204154819-204166322 Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at protein level HPA005131, CAB025903 Approved Renal cancer:6.45e-5 (unfavourable) Tissue enriched Tissue enhanced kidney: 50.8;placenta: 21.0 endometrium: 8.9 RET CDHF12, CDHR16, HSCR1, MEN2A, MEN2B, MTC1, PTC, RET51 ENSG00000165731 Ret proto-oncogene 10 43077027-43130351 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB002581, HPA008356, HPA008495, CAB018342 Approved Supported Supported Vesicles
Plasma membrane
Cytosol Endometrial cancer:5.02e-4 (unfavourable) Tissue enhanced Tissue enriched 5 parathyroid gland: 146.8 adrenal gland: 29.2 RFK FLJ11149, RIFK ENSG00000135002 Riboflavin kinase 9 76385517-76394517 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA023259, CAB033887, HPA057163 Approved Approved Golgi apparatus Expressed in all Expressed in all cerebral cortex: 37.9 RPL3 L3 ENSG00000100316 Ribosomal protein L3 22 39312882-39320389 FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Ribosomal proteins Evidence at protein level HPA003365 Uncertain Supported Nucleoli
Cytosol Expressed in all Expressed in all ovary: 5662.0 RRM1 ENSG00000167325 Ribonucleotide reductase M1 11 4094707-4138876 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB022093, HPA057265, HPA064297 Supported Validated Cytosol Liver cancer:1.53e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 59.5 RRM2 ENSG00000171848 Ribonucleotide reductase M2 2 10122328-10131419 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA056994 Approved Supported Cytosol Renal cancer:0.00e+0 (unfavourable), Liver cancer:1.39e-5 (unfavourable), Pancreatic cancer:1.62e-4 (unfavourable) Expressed in all Mixed lymph node: 47.8 RRM2B p53R2 ENSG00000048392 Ribonucleotide reductase M2 B (TP53 inducible) 8 102204502-102239118 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB006854, HPA028812 Approved Supported Nucleoplasm
Cytosol Expressed in all Expressed in all parathyroid gland: 73.7 RXRA NR2B1 ENSG00000186350 Retinoid X receptor, alpha 9 134317098-134440585 Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB004565, CAB005352 Supported Supported Nucleus
Golgi apparatus Renal cancer:5.58e-4 (unfavourable), Pancreatic cancer:7.02e-4 (favourable) Expressed in all Mixed esophagus: 25.9 RXRB H-2RIIBP, NR2B2, RCoR-1 ENSG00000204231 Retinoid X receptor, beta 6 33193588-33200688 Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB002003, HPA063653 Approved Supported Nucleus Expressed in all Mixed epididymis: 15.5 RXRG NR2B3 ENSG00000143171 Retinoid X receptor, gamma 1 165400917-165445355 Cancer-related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB002615 Uncertain Thyroid cancer:9.40e-5 (favourable) Group enriched Tissue enhanced skeletal muscle: 16.7 cervix, uterine: 4.6 RYR1 CCO, MHS, MHS1, PPP1R137, RYR ENSG00000196218 Ryanodine receptor 1 (skeletal) 19 38433699-38587564 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA056416 Supported Approved Golgi apparatus
Vesicles
Cytosol Mixed Tissue enriched 30 skeletal muscle: 572.4 esophagus: 18.7 S1PR5 Edg-8, EDG8 ENSG00000180739 Sphingosine-1-phosphate receptor 5 19 10512742-10517931 FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA029683 Supported Renal cancer:6.71e-7 (unfavourable) Group enriched Tissue enhanced cerebral cortex: 14.9;skin: 22.1 spleen: 12.2 SCN10A hPN3, Nav1.8, PN3, SNS ENSG00000185313 Sodium channel, voltage gated, type X alpha subunit 3 38696802-38794010 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level Not detected Not detected testis: 0.3 SCN11A NaN, Nav1.9, SCN12A, SNS-2 ENSG00000168356 Sodium channel, voltage gated, type XI alpha subunit 3 38845769-38950561 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA036746, HPA036747 Uncertain Not detected Tissue enhanced placenta: 3.7;spleen: 5.4 testis: 2.1 SCN1A FEB3, GEFSP2, HBSCI, NAC1, Nav1.1, SCN1, SMEI ENSG00000144285 Sodium channel, voltage gated, type I alpha subunit 2 165989160-166128047 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA078664 Approved Nucleoplasm
Nuclear bodies
Plasma membrane Tissue enriched Tissue enhanced cerebral cortex: 12.0;fallopian tube: 4.4;lung: 3.2 testis: 2.2 SCN1B ENSG00000105711 Sodium channel, voltage gated, type I beta subunit 19 35030684-35040448 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Pancreatic cancer:1.38e-4 (favourable) Expressed in all Tissue enhanced skeletal muscle: 133.8 cerebral cortex: 42.7 SCN2A HBSCI, HBSCII, Nav1.2, SCN2A1, SCN2A2 ENSG00000136531 Sodium channel, voltage gated, type II alpha subunit 2 165239402-165392310 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level CAB022567 Supported Tissue enhanced Tissue enriched 22 cerebral cortex: 58.5 kidney: 2.7 SCN2B ENSG00000149575 Sodium channel, voltage gated, type II beta subunit 11 118161951-118176673 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level Mixed Tissue enriched 5 cerebral cortex: 34.8 heart muscle: 6.7 SCN3A Nav1.3 ENSG00000153253 Sodium channel, voltage gated, type III alpha subunit 2 165087522-165204067 FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA035396 Approved Tissue enriched Tissue enriched 6 cerebral cortex: 18.0 adrenal gland: 3.0 SCN3B HSA243396 ENSG00000166257 Sodium channel, voltage gated, type III beta subunit 11 123629187-123655244 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA042518 Approved Nuclear membrane
Cytokinetic bridge Tissue enhanced Tissue enriched 11 cerebral cortex: 132.5 adrenal gland: 11.6 SCN4A HYKPP, HYPP, Nav1.4, SkM1 ENSG00000007314 Sodium channel, voltage gated, type IV alpha subunit 17 63938554-63972918 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA053992 Approved Nucleoplasm
Microtubule organizing center Tissue enhanced Group enriched 9 adipose tissue: 12.3;skeletal muscle: 47.2 thyroid gland: 3.3 SCN4B LQT10 ENSG00000177098 Sodium channel, voltage gated, type IV beta subunit 11 118133377-118152888 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA017293 Approved Mixed Tissue enhanced adipose tissue: 25.0 thyroid gland: 17.0 SCN5A CDCD2, CMD1E, CMPD2, HB1, HB2, HBBD, HH1, ICCD, IVF, LQT3, Nav1.5, PFHB1, SSS1 ENSG00000183873 Sodium channel, voltage gated, type V alpha subunit 3 38548057-38649673 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level Mixed Tissue enriched 18 heart muscle: 26.9 cervix, uterine: 1.5 SCN9A ETHA, Nav1.7, NE-NA, NENA, PN1 ENSG00000169432 Sodium channel, voltage gated, type IX alpha subunit 2 166195185-166375993 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level CAB013679, HPA061843 Uncertain Approved Plasma membrane
Actin filaments
Focal adhesion sites Renal cancer:2.30e-5 (unfavourable) Mixed Tissue enhanced testis: 9.1 placenta: 5.9 SCNN1A ENaCalpha, SCNN1 ENSG00000111319 Sodium channel, non voltage gated 1 alpha subunit 12 6346843-6377730 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA012743 Supported Renal cancer:9.21e-8 (favourable), Pancreatic cancer:2.30e-4 (unfavourable), Ovarian cancer:8.86e-4 (unfavourable) Mixed Mixed cervix, uterine: 94.4 SCNN1B ENaCbeta ENSG00000168447 Sodium channel, non voltage gated 1 beta subunit 16 23278231-23381299 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA015612 Uncertain Renal cancer:2.09e-6 (unfavourable) Tissue enhanced Tissue enhanced cervix, uterine: 71.5 esophagus: 45.0 SCNN1D dNaCh, ENaCdelta ENSG00000162572 Sodium channel, non voltage gated 1 delta subunit 1 1280436-1292029 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB009540, HPA026884 Approved Supported Plasma membrane
Actin filaments Renal cancer:6.67e-5 (unfavourable), Pancreatic cancer:1.32e-4 (favourable), Head and neck cancer:1.60e-4 (favourable) Mixed Tissue enhanced testis: 13.8 cerebral cortex: 7.3 SCNN1G ENaCgamma, SCNEG ENSG00000166828 Sodium channel, non voltage gated 1 gamma subunit 16 23182715-23216883 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA071194 Approved Nucleoplasm
Nucleoli
Plasma membrane Renal cancer:3.20e-7 (unfavourable) Tissue enhanced Tissue enhanced cervix, uterine: 24.5;kidney: 46.4 thyroid gland: 9.5 SCTR ENSG00000080293 Secretin receptor 2 119439843-119525301 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at transcript level HPA007269 Uncertain Tissue enhanced Tissue enhanced duodenum: 27.4;lung: 13.0;pancreas: 14.3 stomach: 4.2 SDHD PGL, PGL1 ENSG00000204370 Succinate dehydrogenase complex, subunit D, integral membrane protein 11 112086773-112120013 Cancer-related genes, Citric acid cycle related proteins, Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA045727 Approved Renal cancer:1.99e-10 (favourable) Expressed in all Expressed in all kidney: 303.5 SERPINB2 HsT1201, PAI2, PLANH2 ENSG00000197632 Serpin peptidase inhibitor, clade B (ovalbumin), member 2 18 63871692-63903890 Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA015480 Supported Approved Golgi apparatus Urothelial cancer:1.55e-5 (unfavourable) Tissue enhanced Group enriched 6 esophagus: 261.7;placenta: 69.7;skin: 106.0;tonsil: 75.5 bone marrow: 22.3 SERPINC1 AT3, ATIII, MGC22579 ENSG00000117601 Serpin peptidase inhibitor, clade C (antithrombin), member 1 1 173903804-173917378 Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA001816, CAB016790, HPA024007 Supported Liver cancer:3.40e-5 (favourable) Tissue enriched Tissue enriched 675 liver: 2511.4 kidney: 3.7 SERPIND1 D22S673, HC-II, HC2, HCF2, HLS2 ENSG00000099937 Serpin peptidase inhibitor, clade D (heparin cofactor), member 1 22 20773879-20787720 Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB008639, HPA055767 Supported Approved Vesicles Endometrial cancer:4.09e-4 (favourable) Tissue enriched Tissue enriched 16 liver: 584.7 parathyroid gland: 35.5 SERPINE1 PAI, PAI1, PLANH1 ENSG00000106366 Serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 7 101127089-101139266 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA050039 Approved Approved Cytosol Renal cancer:5.88e-8 (unfavourable), Stomach cancer:3.27e-6 (unfavourable), Lung cancer:4.41e-6 (unfavourable), Head and neck cancer:2.84e-5 (unfavourable), Colorectal cancer:2.82e-4 (unfavourable), Cervical cancer:5.01e-4 (unfavourable), Urothelial cancer:5.51e-4 (unfavourable) Expressed in all Tissue enhanced gallbladder: 581.0;placenta: 595.2 adipose tissue: 213.2 SHMT1 CSHMT, MGC15229, MGC24556, SHMT ENSG00000176974 Serine hydroxymethyltransferase 1 (soluble) 17 18327860-18363563 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA023314 Approved Supported Nucleus
Cytosol Renal cancer:8.54e-6 (favourable), Liver cancer:2.52e-4 (favourable) Expressed in all Expressed in all kidney: 270.2 SI ENSG00000090402 Sucrase-isomaltase (alpha-glucosidase) 3 164978898-165078495 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA011897 Supported Tissue enhanced Group enriched 15 duodenum: 562.3;small intestine: 503.3 rectum: 34.9 SIGMAR1 OPRS1, SR-BP1 ENSG00000147955 Sigma non-opioid intracellular receptor 1 9 34634722-34637809 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level CAB013470, HPA018002, HPA024071 Approved Urothelial cancer:3.42e-4 (unfavourable) Expressed in all Expressed in all liver: 67.8 SIRT5 ENSG00000124523 Sirtuin 5 6 13574529-13615158 FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA021798, HPA022002, HPA022992 Approved Validated Mitochondria Renal cancer:8.76e-10 (favourable) Expressed in all Expressed in all parathyroid gland: 20.2 SLC12A1 NKCC2 ENSG00000074803 Solute carrier family 12 (sodium/potassium/chloride transporter), member 1 15 48191664-48304078 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA014967, HPA018107 Supported Tissue enhanced Tissue enriched 456 kidney: 773.2 testis: 1.6 SLC12A2 BSC, BSC2, NKCC1, PPP1R141 ENSG00000064651 Solute carrier family 12 (sodium/potassium/chloride transporter), member 2 5 128083766-128189688 FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA020130, HPA063697 Approved Approved Vesicles
Plasma membrane Renal cancer:7.09e-4 (favourable), Endometrial cancer:8.60e-4 (favourable) Expressed in all Expressed in all rectum: 66.4 SLC12A3 NCCT ENSG00000070915 Solute carrier family 12 (sodium/chloride transporter), member 3 16 56865207-56915850 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA028748 Supported Tissue enhanced Tissue enriched 107 kidney: 109.3 lymph node: 1.0 SLC12A4 KCC1 ENSG00000124067 Solute carrier family 12 (potassium/chloride transporter), member 4 16 67943474-67969601 FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA041138 Approved Approved Endosomes Renal cancer:2.25e-6 (favourable) Expressed in all Expressed in all parathyroid gland: 62.5 SLC12A5 KCC2, KIAA1176 ENSG00000124140 Solute carrier family 12 (potassium/chloride transporter), member 5 20 46021690-46060152 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA072058 Supported Glioma:8.45e-4 (unfavourable) Mixed Tissue enriched 8 cerebral cortex: 94.5 adrenal gland: 12.0 SLC18A1 CGAT, VAT1, VMAT1 ENSG00000036565 Solute carrier family 18 (vesicular monoamine transporter), member 1 8 20144855-20183206 FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA006877, HPA063797 Supported Tissue enhanced Tissue enriched 10 adrenal gland: 32.8 rectum: 3.1 SLC18A2 SVAT, SVMT, VMAT2 ENSG00000165646 Solute carrier family 18 (vesicular monoamine transporter), member 2 10 117241093-117279430 FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level Mixed Tissue enhanced cervix, uterine: 43.2 adrenal gland: 19.1 SLC22A11 OAT4 ENSG00000168065 Solute carrier family 22 (organic anion/urate transporter), member 11 11 64555626-64572875 FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA026076 Approved Renal cancer:3.68e-5 (favourable) Group enriched Group enriched 134 epididymis: 10.0;kidney: 25.9;placenta: 44.5 seminal vesicle: 0.2 SLC22A6 OAT1, PAHT, ROAT1 ENSG00000197901 Solute carrier family 22 (organic anion transporter), member 6 11 62936385-62984983 FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level Tissue enriched Tissue enriched 63 kidney: 199.6 cerebral cortex: 3.1 SLC22A8 OAT3 ENSG00000149452 Solute carrier family 22 (organic anion transporter), member 8 11 62989154-63015839 FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA044174 Supported Tissue enhanced Tissue enriched 391 kidney: 337.6 cerebral cortex: 0.8 SLC25A4 ANT1, PEO2, PEO3, T1 ENSG00000151729 Solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 4 4 185143241-185150382 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA046835, HPA071684 Approved Supported Mitochondria Renal cancer:0.00e+0 (favourable), Pancreatic cancer:3.41e-4 (favourable) Expressed in all Tissue enhanced heart muscle: 119.0;skeletal muscle: 66.2 cerebral cortex: 38.2 SLC25A5 2F1, ANT2, T2, T3 ENSG00000005022 Solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 5 X 119468400-119471319 FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA046835, HPA071684 Approved Supported Mitochondria Renal cancer:8.06e-6 (favourable), Cervical cancer:7.35e-4 (favourable), Colorectal cancer:7.47e-4 (favourable) Expressed in all Expressed in all duodenum: 791.0 SLC25A6 ANT3, ANT3Y, MGC17525 ENSG00000169100 Solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 6 X 1386152-1392724 FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA046835, HPA071684 Approved Supported Mitochondria Expressed in all Expressed in all duodenum: 294.5 SLC52A2 D15Ertd747e, FLJ11856, GPCR41, GPR172A, hRFT3, PAR1, RFVT2 ENSG00000185803 Solute carrier family 52 (riboflavin transporter), member 2 8 144354135-144361272 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA063036 Approved Liver cancer:2.04e-6 (unfavourable), Renal cancer:1.23e-4 (unfavourable), Cervical cancer:7.55e-4 (unfavourable) Expressed in all Expressed in all placenta: 24.0 SLC5A2 SGLT2 ENSG00000140675 Solute carrier family 5 (sodium/glucose cotransporter), member 2 16 31483002-31490860 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA041603 Supported Not detected Tissue enriched 9 kidney: 25.3 testis: 2.8 SLC6A1 GABATHG, GABATR, GAT1 ENSG00000157103 Solute carrier family 6 (neurotransmitter transporter), member 1 3 10992724-11039247 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA013341, CAB022293 Supported Uncertain Mitochondria Renal cancer:5.05e-6 (unfavourable), Liver cancer:3.20e-4 (favourable) Group enriched Group enriched 5 cerebral cortex: 119.7;liver: 50.3 parathyroid gland: 15.7 SLC6A2 NAT1, NET, NET1, SLC6A5 ENSG00000103546 Solute carrier family 6 (neurotransmitter transporter), member 2 16 55655604-55706192 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA004057, CAB078195 Supported Supported Approved Mitochondria
Cytosol Tissue enhanced Tissue enhanced adrenal gland: 29.4;placenta: 18.2;skin: 15.7 testis: 11.4 SLC6A3 DAT, DAT1 ENSG00000142319 Solute carrier family 6 (neurotransmitter transporter), member 3 5 1392790-1445430 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA013602, CAB016249, CAB078172 Uncertain Supported Approved Vesicles Renal cancer:3.40e-7 (unfavourable) Tissue enriched Not detected thyroid gland: 0.3 SLC6A4 5-HTT, HTT, OCD1, SERT1 ENSG00000108576 Solute carrier family 6 (neurotransmitter transporter), member 4 17 30194319-30236002 FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA054723, HPA074728 Supported Supported Golgi apparatus
Vesicles Tissue enhanced Group enriched 10 duodenum: 10.7;lung: 44.2;placenta: 26.3;small intestine: 46.2 esophagus: 3.1 SLC6A8 CRTR, CT1 ENSG00000130821 Solute carrier family 6 (neurotransmitter transporter), member 8 X 153688099-153696593 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level Renal cancer:1.53e-4 (unfavourable), Thyroid cancer:7.39e-4 (unfavourable) Expressed in all Mixed small intestine: 90.8 SLC7A11 xCT ENSG00000151012 Solute carrier family 7 (anionic amino acid transporter light chain, xc- system), member 11 4 138164097-138242349 FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA064215 Approved Vesicles Ovarian cancer:1.77e-4 (favourable) Expressed in all Tissue enhanced cerebral cortex: 22.5 epididymis: 8.2 SLC8A1 NCX1 ENSG00000183023 Solute carrier family 8 (sodium/calcium exchanger), member 1 2 40097270-40611053 FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level CAB022694, HPA070007 Uncertain Supported Nucleoplasm
Plasma membrane Mixed Tissue enhanced heart muscle: 79.5 seminal vesicle: 38.2 SLCO2B1 OATP-B, OATP2B1, SLC21A9 ENSG00000137491 Solute carrier organic anion transporter family, member 2B1 11 75100563-75206549 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA020659 Uncertain Expressed in all Expressed in all liver: 123.0 SMO FZD11, SMOH ENSG00000128602 Smoothened, frizzled class receptor 7 129188872-129213545 Cancer-related genes, FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB011446 Approved Expressed in all Mixed ovary: 30.3 SMOX C20orf16, dJ779E11.1, FLJ20746, MGC1010, PAO, PAOh1, SMO ENSG00000088826 Spermine oxidase 20 4120980-4187747 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA047117, HPA060198 Approved Supported Nucleoplasm
Nuclear membrane
Vesicles Liver cancer:3.33e-6 (unfavourable), Renal cancer:1.06e-4 (unfavourable), Lung cancer:1.36e-4 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 49.8 gallbladder: 23.5 SMS MRSR, SPMSY, SpS, SRS ENSG00000102172 Spermine synthase X 21940573-21994835 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA029849, HPA029852 Approved Approved Nuclear bodies
Cytosol Liver cancer:7.79e-8 (unfavourable), Renal cancer:7.85e-5 (unfavourable), Head and neck cancer:7.49e-4 (unfavourable) Expressed in all Expressed in all prostate: 214.9 SNAP25 bA416N4.2, dJ1068F16.2, RIC-4, RIC4, SEC9, SNAP, SNAP-25 ENSG00000132639 Synaptosomal-associated protein, 25kDa 20 10218830-10307418 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Transporters Evidence at protein level CAB000360, HPA001830 Supported Supported Group enriched Tissue enriched 31 cerebral cortex: 1764.2 adrenal gland: 57.4 SOAT1 ACAT, SOAT, STAT ENSG00000057252 Sterol O-acyltransferase 1 1 179293714-179358680 Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level CAB009533, HPA047171 Supported Validated Endoplasmic reticulum Expressed in all Tissue enhanced adrenal gland: 219.3 prostate: 44.0 SPECC1L-ADORA2A ENSG00000258555 SPECC1L-ADORA2A readthrough (NMD candidate) 22 24270898-24442356 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level Not detected Tissue enhanced bone marrow: 15.0;lymph node: 15.2 appendix: 12.5 SQLE ENSG00000104549 Squalene epoxidase 8 124998497-125022283 Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA018038, HPA020762 Approved Uncertain Vesicles
Cytosol Pancreatic cancer:2.73e-4 (unfavourable), Lung cancer:4.67e-4 (unfavourable), Renal cancer:5.70e-4 (unfavourable), Head and neck cancer:7.42e-4 (unfavourable) Expressed in all Mixed testis: 107.2 SRC ASV, c-src, SRC1 ENSG00000197122 SRC proto-oncogene, non-receptor tyrosine kinase 20 37344685-37406050 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004023, HPA030875 Approved Validated Plasma membrane
Cytosol Liver cancer:4.90e-5 (unfavourable), Urothelial cancer:5.22e-5 (favourable), Renal cancer:1.22e-4 (unfavourable), Prostate cancer:1.63e-4 (unfavourable) Expressed in all Mixed gallbladder,small intestine: 43.7 SRD5A1 ENSG00000145545 Steroid-5-alpha-reductase, alpha polypeptide 1 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 1) 5 6633343-6674386 Cancer-related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA051402 Approved Endometrial cancer:8.73e-6 (unfavourable) Expressed in all Mixed skin: 17.1 SRD5A2 ENSG00000277893 Steroid-5-alpha-reductase, alpha polypeptide 2 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 2) 2 31522480-31581067 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level Group enriched Group enriched 11 epididymis: 27.4;fallopian tube: 31.2;liver: 30.6;prostate: 25.3;seminal vesicle: 24.2 testis: 2.4 SSTR1 ENSG00000139874 Somatostatin receptor 1 14 38207999-38213067 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA031506 Approved Renal cancer:4.28e-4 (favourable) Mixed Tissue enhanced cerebral cortex: 13.6;duodenum: 14.6;stomach: 21.4 small intestine: 9.3 SSTR2 ENSG00000180616 Somatostatin receptor 2 17 73165012-73176633 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA007264 Uncertain Supported Cytosol Renal cancer:9.04e-7 (unfavourable), Pancreatic cancer:6.63e-4 (favourable) Mixed Tissue enhanced cerebral cortex: 22.9 spleen: 5.9 SSTR5 ENSG00000162009 Somatostatin receptor 5 16 1078781-1080142 FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA066503 Supported Plasma membrane Mixed Tissue enhanced adrenal gland: 1.2 heart muscle: 0.8 SV2A KIAA0736, SV2 ENSG00000159164 Synaptic vesicle glycoprotein 2A 1 149903318-149917882 FDA approved drug targets, Predicted membrane proteins Evidence at protein level CAB002226, HPA007863 Supported Approved Cytosol Renal cancer:3.22e-4 (unfavourable) Tissue enriched Tissue enhanced cerebral cortex: 167.4;parathyroid gland: 70.8 epididymis: 27.9 SYT2 ENSG00000143858 Synaptotagmin II 1 202590596-202710417 Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA030372, HPA063655 Supported Approved Vesicles Tissue enriched Tissue enhanced cerebral cortex: 2.1 adrenal gland: 1.8 TAAR1 TA1, TAR1, TRAR1 ENSG00000146399 Trace amine associated receptor 1 6 132644984-132646003 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA055614 Approved Tissue enhanced Group enriched 17 fallopian tube: 2.2;stomach: 7.9 duodenum,endometrium,prostate,urinary bladder: 0.2 TACR1 NK1R, NKIR, SPR, TAC1R ENSG00000115353 Tachykinin receptor 1 2 75046463-75199700 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA074573 Approved Mixed Tissue enhanced cervix, uterine: 7.3 fallopian tube: 4.7 TBXA2R ENSG00000006638 Thromboxane A2 receptor 19 3594506-3606840 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA077366 Supported Nuclear speckles
Plasma membrane Renal cancer:1.45e-4 (unfavourable), Pancreatic cancer:7.17e-4 (favourable) Expressed in all Mixed spleen: 5.3 TBXAS1 CYP5, CYP5A1, THAS, TS, TXAS, TXS ENSG00000059377 Thromboxane A synthase 1 (platelet) 7 139777051-140020325 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA031257, HPA031258, HPA031259 Supported Supported Vesicles Renal cancer:1.14e-4 (unfavourable) Expressed in all Mixed spleen: 57.1 TEK CD202b, TIE-2, TIE2, VMCM, VMCM1 ENSG00000120156 TEK tyrosine kinase, endothelial 9 27109141-27230175 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB010359, HPA073265 Approved Supported Plasma membrane
Microtubule organizing center Liver cancer:2.31e-5 (favourable), Renal cancer:7.81e-4 (favourable) Expressed in all Tissue enhanced placenta: 65.3 lung: 42.7 TFPI EPI, LACI, TFI, TFPI1 ENSG00000003436 Tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor) 2 187464230-187565760 Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA005575, CAB020842 Supported Approved Intermediate filaments
Cytosol Cervical cancer:2.02e-4 (unfavourable) Expressed in all Expressed in all placenta: 340.4 TH DYT5b ENSG00000180176 Tyrosine hydroxylase 11 2163929-2171877 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level CAB002522, HPA061003, CAB072340 Supported Supported Tissue enhanced Tissue enriched 81 adrenal gland: 261.2 adipose tissue: 3.2 THRA AR7, EAR-7.1/EAR-7.2, ERBA, ERBA1, NR1A1, THRA1, THRA2, THRA3 ENSG00000126351 Thyroid hormone receptor, alpha 17 40058290-40093867 Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA009654, CAB023349 Uncertain Supported Cytosol Renal cancer:6.05e-8 (favourable), Lung cancer:1.84e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 239.6 THRB ERBA-BETA, ERBA2, GRTH, NR1A2, PRTH, THR1, THRB1, THRB2 ENSG00000151090 Thyroid hormone receptor, beta 3 24117160-24495282 Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB002008, CAB002009, HPA061035 Approved Supported Nuclear bodies Renal cancer:9.46e-8 (favourable) Mixed Mixed cerebral cortex: 36.4 TLR2 CD282, TIL4 ENSG00000137462 Toll-like receptor 2 4 153701500-153705699 CD markers, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA060231, HPA071546 Supported Nucleus
Mitochondria Renal cancer:1.11e-4 (unfavourable) Expressed in all Tissue enhanced appendix: 53.7 bone marrow: 34.9 TLR7 ENSG00000196664 Toll-like receptor 7 X 12867083-12890380 FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA059613 Supported Mixed Mixed placenta: 9.1 TLR9 CD289 ENSG00000239732 Toll-like receptor 9 3 52221080-52226163 CD markers, FDA approved drug targets, Predicted membrane proteins Evidence at protein level Not detected Tissue enhanced lymph node: 3.0 spleen: 2.0 TNF DIF, TNF-alpha, TNFA, TNFSF2 ENSG00000232810 Tumor necrosis factor 6 31575567-31578336 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level Mixed Tissue enhanced bone marrow: 3.7 lymph node: 1.3 TNFRSF8 CD30, D1S166E, KI-1 ENSG00000120949 Tumor necrosis factor receptor superfamily, member 8 1 12063377-12144207 Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB000016, HPA032081, HPA032082 Approved Tissue enriched Tissue enhanced appendix: 4.3 adipose tissue: 3.1 TNFSF11 CD254, ODF, OPGL, RANKL, TRANCE ENSG00000120659 Tumor necrosis factor (ligand) superfamily, member 11 13 42562736-42608013 Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB009193, HPA045142 Supported Mixed Tissue enhanced lymph node: 17.6 appendix: 6.5 TNFSF13B BAFF, BLYS, CD257, TALL-1, TALL1, THANK, TNFSF20 ENSG00000102524 Tumor necrosis factor (ligand) superfamily, member 13b 13 108251240-108308484 Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB009188 Approved Renal cancer:2.53e-11 (unfavourable) Expressed in all Mixed appendix: 36.2 TNNC1 TNNC ENSG00000114854 Troponin C type 1 (slow) 3 52451102-52454070 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002450, HPA044848, HPA056897 Supported Approved Nucleoplasm
Actin filaments
Mitochondria Mixed Group enriched 15 heart muscle: 4358.3;skeletal muscle: 7106.5 esophagus: 385.2 TOP1 ENSG00000198900 Topoisomerase (DNA) I 20 41028818-41124487 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level CAB009058, HPA019039 Supported Supported Nucleus
Nucleoli fibrillar center Liver cancer:6.42e-4 (unfavourable) Expressed in all Expressed in all lymph node: 71.8 TOP1MT ENSG00000184428 Topoisomerase (DNA) I, mitochondrial 8 143304384-143359979 Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA001915, HPA021542 Approved Supported Mitochondria Renal cancer:1.52e-7 (unfavourable) Expressed in all Expressed in all testis: 41.2 TOP2A TOP2 ENSG00000131747 Topoisomerase (DNA) II alpha 17 40388516-40417950 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002448, HPA006458, HPA026773 Supported Validated Nucleus
Nucleoli Renal cancer:0.00e+0 (unfavourable), Liver cancer:5.92e-6 (unfavourable), Pancreatic cancer:3.83e-5 (unfavourable), Lung cancer:4.99e-4 (unfavourable) Expressed in all Tissue enhanced testis: 108.0 lymph node: 48.2 TOP2B ENSG00000077097 Topoisomerase (DNA) II beta 3 25597905-25664907 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004601, HPA024120, HPA050441 Supported Validated Nucleus Liver cancer:1.86e-7 (unfavourable), Renal cancer:2.43e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 105.5 TPH1 TPH, TPRH ENSG00000129167 Tryptophan hydroxylase 1 11 18017564-18042426 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level CAB010767, HPA022483 Supported Uncertain Cytosol Mixed Group enriched 6 colon: 9.0;duodenum: 10.5;rectum: 21.3;small intestine: 12.9;stomach: 15.5 prostate: 2.2 TPK1 HTPK1, PP20 ENSG00000196511 Thiamin pyrophosphokinase 1 7 144451941-144836395 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA021545, HPA021849 Approved Approved Vesicles Mixed Mixed duodenum: 14.4 TPMT ENSG00000137364 Thiopurine S-methyltransferase 6 18128311-18155074 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA019851 Approved Endometrial cancer:8.45e-5 (unfavourable), Renal cancer:1.10e-4 (favourable), Ovarian cancer:1.41e-4 (favourable) Expressed in all Expressed in all thyroid gland: 129.4 TPO TPX ENSG00000115705 Thyroid peroxidase 2 1374223-1543711 Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA007987, CAB009587 Supported Tissue enriched Tissue enriched 101 thyroid gland: 1811.8 spleen: 17.9 TRPA1 ANKTM1 ENSG00000104321 Transient receptor potential cation channel, subfamily A, member 1 8 72019917-72075617 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA026630 Uncertain Colorectal cancer:6.57e-4 (favourable) Mixed Tissue enhanced urinary bladder: 30.5 gallbladder: 11.4 TRPM8 ENSG00000144481 Transient receptor potential cation channel, subfamily M, member 8 2 233917398-234019522 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level Liver cancer:7.15e-4 (favourable) Tissue enriched Tissue enriched 8 prostate: 128.7 liver: 16.3 TRPV1 VR1 ENSG00000196689 Transient receptor potential cation channel, subfamily V, member 1 17 3565444-3609411 FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level Not detected Mixed duodenum: 8.0 TRPV3 VRL3 ENSG00000167723 Transient receptor potential cation channel, subfamily V, member 3 17 3510502-3557995 Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA069550 Approved Plasma membrane
Centrosome
Cytosol Mixed Tissue enhanced skin: 5.2;small intestine: 4.6 duodenum: 1.7 TSHR LGR3 ENSG00000165409 Thyroid stimulating hormone receptor 14 80954989-81146302 Cancer-related genes, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB000473 Approved Tissue enriched Tissue enriched 277 thyroid gland: 443.8 lymph node: 1.6 TSPO BZRP, DBI, IBP, MBR, mDRC, PBR, pk18, PKBS ENSG00000100300 Translocator protein (18kDa) 22 43151514-43163242 Cancer-related genes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB011232, HPA046260 Uncertain Approved Vesicles
Mitochondria
Cytosol Liver cancer:1.61e-4 (unfavourable) Expressed in all Expressed in all bone marrow: 301.2 TUBA1A B-ALPHA-1, FLJ25113, TUBA3 ENSG00000167552 Tubulin, alpha 1a 12 49184796-49189324 Cancer-related genes, Disease related genes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level CAB008686, HPA039247, HPA043684, HPA063394 Supported Validated Microtubules Renal cancer:2.90e-4 (unfavourable) Tissue enriched Expressed in all cerebral cortex: 1377.5 TUBA4A FLJ30169, H2-ALPHA, TUBA1 ENSG00000127824 Tubulin, alpha 4a 2 219249711-219278170 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004621, CAB005887, HPA039247, HPA043684, HPA063394 Approved Validated Microtubules Liver cancer:4.54e-6 (unfavourable) Expressed in all Expressed in all skin: 181.9 TUBB M40, MGC16435, OK/SW-cl.56, Tubb5 ENSG00000196230 Tubulin, beta class I 6 30720201-30725426 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB005417, CAB012406, HPA043640, HPA046280 Supported Validated Microtubules Renal cancer:2.62e-8 (unfavourable), Liver cancer:5.97e-4 (unfavourable) Expressed in all Expressed in all ovary: 71.9 TUBB1 dJ543J19.4 ENSG00000101162 Tubulin, beta 1 class VI 20 59019254-59026654 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004286, HPA043640, HPA046280 Approved Supported Microtubules Not detected Group enriched 5 bone marrow: 4.8;lung: 1.9;placenta: 1.2;spleen: 5.3;testis: 1.5 gallbladder: 0.5 TUBB3 beta-4, CFEOM3, CFEOM3A, FEOM3 ENSG00000258947 Tubulin, beta 3 class III 16 89921392-89938761 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA043640, HPA046280 Approved Supported Microtubules Mixed Tissue enriched 6 cerebral cortex: 196.2 adrenal gland: 34.7 TUBB4B Beta2, TUBB2C ENSG00000188229 Tubulin, beta 4B class IVb 9 137241213-137243707 FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB010880, HPA043640, HPA046280 Supported Validated Microtubules Thyroid cancer:6.36e-6 (favourable), Endometrial cancer:4.91e-4 (favourable), Liver cancer:9.98e-4 (unfavourable) Expressed in all Expressed in all testis: 787.0 TUBD1 FLJ12709, TUBD ENSG00000108423 Tubulin, delta 1 17 59859482-59892945 FDA approved drug targets, Predicted intracellular proteins Evidence at protein level CAB004609, HPA023980, HPA027090 Approved Validated Nucleoplasm
Cytosol Liver cancer:1.00e-5 (unfavourable), Colorectal cancer:2.04e-4 (favourable), Renal cancer:6.06e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 12.7 TUBE1 dJ142L7.2, FLJ22589, TUBE ENSG00000074935 Tubulin, epsilon 1 6 112070777-112087529 FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA032073, HPA032074 Approved Expressed in all Expressed in all testis: 54.9 TUBG1 TUBG, TUBGCP1 ENSG00000131462 Tubulin, gamma 1 17 42609676-42615234 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004608 Approved Liver cancer:1.08e-8 (unfavourable), Renal cancer:6.48e-5 (unfavourable), Endometrial cancer:8.99e-4 (favourable) Expressed in all Tissue enriched 6 testis: 242.4 smooth muscle: 39.7 TXNRD1 GRIM-12, Trxr1, TXNR ENSG00000198431 Thioredoxin reductase 1 12 104215779-104350305 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA001395, CAB004607, CAB015834, HPA043871 Approved Supported Nucleus Liver cancer:1.12e-5 (unfavourable), Renal cancer:1.20e-5 (unfavourable) Expressed in all Expressed in all adrenal gland: 109.8 TYMS HsT422, TMS, TS, Tsase ENSG00000176890 Thymidylate synthetase 18 657604-673578 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002784 Approved Liver cancer:5.10e-6 (unfavourable) Expressed in all Mixed testis: 58.9 TYR OCA1, OCA1A, OCAIA ENSG00000077498 Tyrosinase 11 89177452-89295759 Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level CAB000079, HPA043241, HPA050889 Supported Validated Vesicles Tissue enriched Tissue enriched 33 skin: 29.9 breast: 0.9 UGCG GCS ENSG00000148154 UDP-glucose ceramide glucosyltransferase 9 111896766-111935369 Enzymes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA024124 Approved Endometrial cancer:4.44e-5 (favourable), Cervical cancer:6.62e-4 (favourable) Expressed in all Expressed in all adrenal gland: 84.4 VAMP1 SYB1, VAMP-1 ENSG00000139190 Vesicle-associated membrane protein 1 (synaptobrevin 1) 12 6462237-6470987 FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB002779, CAB016119 Approved Renal cancer:1.04e-11 (unfavourable), Colorectal cancer:6.37e-5 (unfavourable), Liver cancer:6.97e-4 (unfavourable) Expressed in all Mixed cerebral cortex: 43.6 VAMP2 SYB2, VAMP-2 ENSG00000220205 Vesicle-associated membrane protein 2 (synaptobrevin 2) 17 8159149-8163546 FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB078785 Supported Renal cancer:9.76e-8 (favourable), Pancreatic cancer:3.83e-6 (favourable), Endometrial cancer:1.08e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 485.0 VDR NR1I1, PPP1R163 ENSG00000111424 Vitamin D (1,25- dihydroxyvitamin D3) receptor 12 47841537-47943048 Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB004617, HPA047740 Validated Nucleoplasm Renal cancer:4.89e-6 (favourable) Expressed in all Tissue enhanced parathyroid gland: 172.8 small intestine: 59.2 VEGFA VEGF, VEGF-A, VPF ENSG00000112715 Vascular endothelial growth factor A 6 43770184-43786487 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB005429, CAB039240, HPA069116 Approved Renal cancer:1.76e-5 (unfavourable), Liver cancer:2.34e-5 (unfavourable), Endometrial cancer:2.10e-4 (unfavourable), Urothelial cancer:2.73e-4 (favourable), Cervical cancer:4.50e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 455.6 VEGFB VEGFL, VRF ENSG00000173511 Vascular endothelial growth factor B 11 64234538-64238793 Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level Expressed in all Expressed in all adipose tissue: 194.9 VKORC1 VKCFD2 ENSG00000167397 Vitamin K epoxide reductase complex, subunit 1 16 31090842-31095980 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA042720 Approved Renal cancer:2.09e-10 (unfavourable) Expressed in all Expressed in all liver: 141.1 VKORC1L1 ENSG00000196715 Vitamin K epoxide reductase complex, subunit 1-like 1 7 65873267-65959563 Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA053954 Approved Supported Endoplasmic reticulum Expressed in all Expressed in all adipose tissue: 57.3 VWF F8VWF ENSG00000110799 Von Willebrand factor 12 5948874-6124770 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB001694, HPA001815, HPA002082, CAB072874, CAB072875 Supported Stomach cancer:2.31e-4 (unfavourable) Expressed in all Mixed adipose tissue: 154.4 XDH XO, XOR ENSG00000158125 Xanthine dehydrogenase 2 31334321-31414715 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA062641, HPA069323 Supported Supported Nucleus Urothelial cancer:8.73e-6 (favourable) Mixed Tissue enhanced breast: 48.6;duodenum: 46.9;liver: 35.9;small intestine: 55.8 colon: 11.4 YES1 c-yes, HsT441, Yes ENSG00000176105 YES proto-oncogene 1, Src family tyrosine kinase 18 721588-812546 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004370, HPA026480 Approved Supported Plasma membrane
Cytosol Pancreatic cancer:2.46e-4 (unfavourable) Expressed in all Expressed in all placenta: 61.6